Existing Annotations Review

GO Term	Evidence	Action	Reason
GO:0008484 sulfuric ester hydrolase activity	IBA GO_REF:0000033	ACCEPT	Summary: This IBA annotation correctly identifies ARSB as a sulfuric ester hydrolase, which is accurate as ARSB catalyzes hydrolysis of sulfate ester bonds. This is the broader enzymatic class encompassing the more specific N-acetylgalactosamine-4-sulfatase activity. The phylogenetic evidence supporting this annotation is strong across mammalian orthologs. Reason: This is an appropriate molecular function term that accurately reflects the core catalytic activity of ARSB. While more general than the specific N-acetylgalactosamine-4-sulfatase activity, it correctly places ARSB in the sulfatase family. The IBA evidence based on phylogenetic conservation is robust. Supporting Evidence: PMID:2303452 Deduced amino acid sequences of human arylsulfatase A, human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and an arylsulfatase from sea urchin showed a substantial degree of similarity suggesting that they arose from a common ancestral gene and are members of an arylsulfatase gene family. file:human/ARSB/ARSB-uniprot.txt RecName: Full=Arylsulfatase B; Short=ASB; EC=3.1.6.12 file:human/ARSB/ARSB-deep-research-falcon.md See deep research file for comprehensive analysis
GO:0003943 N-acetylgalactosamine-4-sulfatase activity	IEA GO_REF:0000003	ACCEPT	Summary: This annotation correctly identifies the specific enzymatic activity of ARSB. The EC mapping (EC:3.1.6.12) accurately reflects that ARSB catalyzes the hydrolysis of 4-sulfate groups from N-acetylgalactosamine residues in both chondroitin sulfate and dermatan sulfate. This is the primary and most specific molecular function of ARSB. Reason: This is the most precise molecular function term for ARSB and should be retained as a core annotation. Although this is IEA based on EC mapping, it is also supported by multiple experimental studies (IDA annotations from PMID:18285341 and PMID:19306108). Supporting Evidence: PMID:18285341 The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze sulfate groups of CS. PMID:19306108 Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase; 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form the disaccharide unit of chondroitin-4-sulfate (C4S). Reactome:R-HSA-1793207 Arylsulfatase B using calcium cofactor (ARSB:Ca2+) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate) units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
GO:0004065 arylsulfatase activity	IEA GO_REF:0000117	ACCEPT	Summary: This annotation identifies ARSB as having arylsulfatase activity, which is a broader classification than the specific N-acetylgalactosamine-4-sulfatase activity. While technically correct, this term is somewhat less informative than GO:0003943. Reason: This annotation is correct and reflects the arylsulfatase family membership of ARSB. Although broader than the specific sulfatase activity, it is appropriate to retain this alongside the more specific term, as it reflects the historical nomenclature and biochemical classification. This is also supported by a TAS annotation. Supporting Evidence: PMID:2303452 Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B. [...] members of an arylsulfatase gene family. file:human/ARSB/ARSB-uniprot.txt RecName: Full=Arylsulfatase B
GO:0005764 lysosome	IEA GO_REF:0000044	ACCEPT	Summary: This annotation correctly places ARSB in the lysosome, which is the primary and well-established cellular compartment where ARSB functions. ARSB is a classical lysosomal enzyme that degrades glycosaminoglycans in this organelle. Reason: This is a core cellular component annotation for ARSB. The lysosomal localization is extensively documented and is the primary site of ARSB function in glycosaminoglycan degradation. This is supported by both IEA and TAS evidence, as well as the original biochemical characterization of the enzyme. Supporting Evidence: PMID:2303452 The 47-kDa ASB form was located in dense lysosomes. Transport of ASB to the lysosomes was accomplished in a mannose 6-phosphate receptor-dependent manner. file:human/ARSB/ARSB-uniprot.txt SUBCELLULAR LOCATION: Lysosome file:human/ARSB/ARSB-deep-research-perplexity-lite.md Primary: ARSB is predominantly a lysosomal enzyme
GO:0008484 sulfuric ester hydrolase activity	IEA GO_REF:0000120	ACCEPT	Summary: This is a duplicate annotation of the IBA sulfuric ester hydrolase activity annotation (line 2 of GOA file), but with different evidence (IEA from combined automated methods) and ortholog mapping to rat ARSB. Reason: While this is a duplicate GO term, it represents independent evidence from automated orthology mapping, which reinforces the IBA annotation. It is acceptable to have the same term with different evidence codes. Supporting Evidence: PMID:2303452 Deduced amino acid sequences of human arylsulfatase A, human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and an arylsulfatase from sea urchin showed a substantial degree of similarity
GO:0009986 cell surface	IEA GO_REF:0000120	ACCEPT	Summary: This annotation indicates ARSB localizes to the cell surface. While ARSB is primarily lysosomal, there is evidence from UniProt and literature that ARSB can be detected at the cell membrane in certain cell types, particularly in colonic and prostatic epithelial cells. This extra-lysosomal localization may have functional significance. Reason: Although ARSB is predominantly a lysosomal enzyme, the evidence for cell surface localization should not be dismissed. The deep research document notes that ARSB has been detected at cell membranes, and this may represent a non-core but biologically relevant localization. There is also an ISS annotation supporting this. Supporting Evidence: file:human/ARSB/ARSB-deep-research-perplexity-lite.md Extra-lysosomal: Immunohistochemistry and immunofluorescence studies have also detected ARSB at the cell membrane of hepatocytes, sinusoidal endothelial cells, Kupffer cells, and the apical membranes of colonic and prostatic epithelial cells. Membrane localization is reduced in malignant tissues. file:human/ARSB/ARSB-uniprot.txt SUBCELLULAR LOCATION: Lysosome. Cell surface.
GO:0016787 hydrolase activity	IEA GO_REF:0000043	ACCEPT	Summary: This is a very broad molecular function term indicating that ARSB is a hydrolase, which is technically correct but not informative. This term is the parent of more specific terms like sulfuric ester hydrolase activity. Reason: While this term is extremely broad and not very informative, it is technically correct and represents the top-level enzymatic classification. It is acceptable to keep this alongside more specific terms, as it may be useful for broad queries. However, this is clearly less informative than the more specific sulfatase activity terms. Supporting Evidence: file:human/ARSB/ARSB-uniprot.txt EC=3.1.6.12 [hydrolase class]
GO:0046872 metal ion binding	IEA GO_REF:0000043	MODIFY	Summary: This annotation indicates metal ion binding activity. ARSB requires calcium as a cofactor, binding one Ca2+ ion per subunit. The term is somewhat generic but is biochemically accurate. Reason: While ARSB does bind metal ions, specifically calcium, the current term is too generic. A more specific term would be calcium ion binding (GO:0005509), which accurately reflects the specific metal requirement documented in UniProt and Reactome. The current term should be replaced with the more specific calcium ion binding term. Proposed replacements: calcium ion binding Supporting Evidence: file:human/ARSB/ARSB-uniprot.txt COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds 1 Ca(2+) ion per subunit. Reactome:R-HSA-1793207 Arylsulfatase B using calcium cofactor (ARSB:Ca2+) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate
GO:0006914 autophagy	IEA GO_REF:0000107	REMOVE	Summary: This annotation suggests ARSB is involved in autophagy, based on orthology to rat ARSB. While ARSB is a lysosomal enzyme and lysosomes are involved in autophagy, there is no direct evidence that ARSB specifically participates in autophagic processes beyond being a general lysosomal enzyme. Reason: This annotation appears to be an over-annotation. While ARSB is lysosomal and lysosomes participate in autophagy, there is no specific evidence that ARSB has a direct functional role in autophagy itself. ARSB's primary function is glycosaminoglycan degradation, not autophagy regulation. This annotation likely arises from guilt-by-association with the lysosome rather than a specific biological role. Supporting Evidence: file:human/ARSB/ARSB-deep-research-perplexity-lite.md ARSB encodes the enzyme N-acetylgalactosamine-4-sulfatase, which hydrolyzes (removes) 4-sulfate groups from the GAGs dermatan sulfate and chondroitin-4-sulfate [does not mention autophagy as a specific function]
GO:0007584 response to nutrient	IEA GO_REF:0000107	REMOVE	Summary: This annotation suggests ARSB is involved in response to nutrient, based on orthology to rat. There is no specific evidence that ARSB responds to or regulates nutrient sensing beyond its general role as a lysosomal enzyme. Reason: This appears to be an over-annotation without specific supporting evidence. While lysosomal function can be influenced by nutrient status, there is no indication that ARSB specifically mediates nutrient response pathways. This annotation likely reflects general lysosomal biology rather than a specific ARSB function.
GO:0009268 response to pH	IEA GO_REF:0000107	REMOVE	Summary: This annotation indicates ARSB is involved in response to pH. As a lysosomal enzyme, ARSB functions optimally at acidic pH (the lysosomal environment), but there is no evidence it specifically responds to or regulates pH. Reason: This is an over-annotation. While ARSB activity is pH-dependent (like most lysosomal enzymes that function optimally at acidic pH), this does not mean ARSB is involved in pH response as a biological process. The term implies ARSB actively participates in sensing or responding to pH changes, which is not supported by evidence.
GO:0010976 positive regulation of neuron projection development	IEA GO_REF:0000107	KEEP AS NON CORE	Summary: This annotation suggests ARSB positively regulates neuron projection development, based on orthology to rat. UniProt states that in the central nervous system, ARSB is a regulator of neurite outgrowth and neuronal plasticity through control of sulfate glycosaminoglycans and neurocan levels, though this is based on similarity evidence. Reason: While there is supporting evidence from UniProt (based on similarity) that ARSB regulates neurite outgrowth in the CNS, this appears to be a non-core, tissue-specific function rather than a primary function of ARSB. The core function is glycosaminoglycan degradation; the neuronal effects are downstream consequences of this activity in neural tissue. This should be retained but marked as non-core. Supporting Evidence: file:human/ARSB/ARSB-uniprot.txt In the central nervous system, is a regulator of neurite outgrowth and neuronal plasticity, acting through the control of sulfate glycosaminoglycans and neurocan levels (By similarity). file:human/ARSB/ARSB-deep-research-perplexity-lite.md Neuronal development: In the central nervous system, ARSB regulates neurite outgrowth and neuronal plasticity by controlling sulfate GAG and neurocan levels
GO:0043627 response to estrogen	IEA GO_REF:0000107	REMOVE	Summary: This annotation suggests ARSB is involved in response to estrogen, based on orthology to rat. There is no specific evidence in the literature or UniProt that ARSB directly responds to or mediates estrogen signaling. Reason: This appears to be an over-annotation without supporting evidence. While ARSB expression levels might be influenced by various factors including hormones, there is no specific evidence that ARSB plays a role in estrogen response pathways. This annotation should be removed unless specific evidence emerges.
GO:0051597 response to methylmercury	IEA GO_REF:0000107	REMOVE	Summary: This annotation suggests ARSB is involved in response to methylmercury, based on orthology to rat. This appears to be an artifact of expression studies in rats and does not reflect a specific biological function of ARSB. Reason: This is an over-annotation that likely reflects experimental conditions in rat studies rather than a genuine biological function. There is no evidence that ARSB has a specific role in methylmercury response or detoxification. This should be removed.
GO:0003943 N-acetylgalactosamine-4-sulfatase activity	IDA PMID:18285341 Distinct effects of N-acetylgalactosamine-4-sulfatase and ga...	ACCEPT	Summary: This is experimental (IDA) confirmation of the specific N-acetylgalactosamine-4-sulfatase activity of ARSB. The study directly demonstrated that ARSB hydrolyzes sulfate groups from chondroitin sulfates and that modifying ARSB expression affects chondroitin-4-sulfate levels. Reason: This is a gold-standard experimental annotation that directly demonstrates the primary molecular function of ARSB. This is core evidence supporting the specific enzymatic activity and should definitely be retained. Supporting Evidence: PMID:18285341 The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze sulfate groups of CS. [...] Following silencing of ASB or GALNS, total sGAG, C4S, and CS increased significantly. Following overexpression of ASB or GALNS, total sGAG, C4S, and CS declined significantly.
GO:0030207 chondroitin sulfate proteoglycan catabolic process	IDA PMID:18285341 Distinct effects of N-acetylgalactosamine-4-sulfatase and ga...	ACCEPT	Summary: This experimental annotation indicates ARSB is involved in chondroitin sulfate proteoglycan catabolism. The study demonstrated that ARSB expression affects the content of chondroitin sulfate and its proteoglycans, with overexpression leading to reduced CS and increased syndecan-1 and decorin core protein expression. Reason: This annotation is well-supported by experimental evidence. The study shows that ARSB affects both the glycosaminoglycan chains and the proteoglycan content, justifying annotation to the proteoglycan catabolic process. ARSB's enzymatic removal of sulfate groups from chondroitin sulfate chains is a key step in proteoglycan degradation. Supporting Evidence: PMID:18285341 Following silencing of ASB or GALNS, total sGAG, C4S, and CS increased significantly. Following overexpression of ASB or GALNS, total sGAG, C4S, and CS declined significantly. PMID:18285341 mRNA expression of core proteins of the CS-containing proteoglycans, syndecan-1 and decorin, was significantly up-regulated following overexpression of ASB
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-2282889	ACCEPT	Summary: This annotation places ARSB in the lysosomal lumen based on Reactome pathway annotation for defective ARSB in MPS VI. The lysosomal lumen is indeed where ARSB functions to degrade glycosaminoglycans. Reason: This is an accurate and specific cellular component annotation. ARSB is a soluble lysosomal enzyme that functions in the lysosomal lumen, where it encounters its substrates during glycosaminoglycan degradation. This is more specific than just "lysosome" and should be retained. Supporting Evidence: PMID:2303452 The 47-kDa ASB form was located in dense lysosomes. Reactome:R-HSA-2282889 Defective ARSB does not hydrolyse C4S/C6S chains [implies ARSB functions in lysosomal lumen]
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-9036065	ACCEPT	Summary: This is another TAS annotation for lysosomal lumen from a different Reactome pathway (defective ARSB not hydrolyzing dermatan sulfate). This is a duplicate of the previous annotation but from a different pathway. Reason: While this is a duplicate GO term, it represents independent evidence from a different Reactome pathway, which reinforces the localization. It is acceptable to have the same term with different references. Supporting Evidence: Reactome:R-HSA-9036065 Defective ARSB does not hydrolyse DS
GO:0005576 extracellular region	TAS Reactome:R-HSA-6798751	KEEP AS NON CORE	Summary: This annotation indicates ARSB is found in the extracellular region, specifically in the context of azurophil granule exocytosis from neutrophils. ARSB can be secreted and found extracellularly. Reason: While ARSB is primarily a lysosomal enzyme, it can be secreted and found in the extracellular region, particularly during neutrophil degranulation. This represents a non-core localization that is biologically relevant but secondary to the main lysosomal function. The annotation should be retained but marked as non-core. Supporting Evidence: Reactome:R-HSA-6798751 Exocytosis of azurophil granule lumen proteins [ARSB is among the proteins released] file:human/ARSB/ARSB-deep-research-perplexity-lite.md ARSB is predominantly a lysosomal enzyme. Extra-lysosomal [localizations exist]
GO:0005576 extracellular region	TAS Reactome:R-HSA-6800434	KEEP AS NON CORE	Summary: This is another annotation for extracellular region from Reactome, this time in the context of ficolin-1-rich granule exocytosis. This is a duplicate GO term with different supporting evidence. Reason: This reinforces the extracellular localization through a different pathway (ficolin-rich granule exocytosis). As with the previous extracellular region annotation, this is a non-core localization but should be retained. Supporting Evidence: Reactome:R-HSA-6800434 Exocytosis of ficolin-rich granule lumen proteins [ARSB is among the proteins released]
GO:0035578 azurophil granule lumen	TAS Reactome:R-HSA-6798751	KEEP AS NON CORE	Summary: This annotation places ARSB in azurophil granule lumen of neutrophils. Azurophil granules are specialized secretory granules in neutrophils that can contain lysosomal enzymes. Reason: This is a specialized, cell-type-specific localization of ARSB in neutrophils. While accurate, this represents a non-core localization specific to neutrophils and their degranulation processes. This should be retained as it is supported by Reactome but marked as non-core. Supporting Evidence: Reactome:R-HSA-6798751 Azurophil granules are generally described as spherical. Like lysosomes, they contain CD63 in their membrane (Cham et al. 1994) but are regarded as specialized secretory granules rather than lysosomes (Cieutat et al. 1998)
GO:1904813 ficolin-1-rich granule lumen	TAS Reactome:R-HSA-6800434	KEEP AS NON CORE	Summary: This annotation places ARSB in ficolin-1-rich granule lumen, another type of secretory granule in neutrophils. This is a very specific, cell-type-restricted localization. Reason: This is an extremely specific cellular compartment in neutrophils. While the annotation is supported by Reactome, it represents a highly specialized, non-core localization. It should be retained for completeness but clearly marked as non-core and cell-type-specific. Supporting Evidence: Reactome:R-HSA-6800434 Exocytosis of ficolin-rich granule lumen proteins
GO:0003943 N-acetylgalactosamine-4-sulfatase activity	IDA PMID:19306108 Arylsulfatase B regulates colonic epithelial cell migration ...	ACCEPT	Summary: This is another experimental (IDA) confirmation of ARSB's N-acetylgalactosamine-4-sulfatase activity from a different study. This study demonstrated that modulating ARSB expression affects chondroitin-4-sulfate content and related cellular functions. Reason: This is independent experimental evidence for the core molecular function of ARSB. Having multiple IDA annotations from different studies strengthens the evidence for this critical activity. This should definitely be retained. Supporting Evidence: PMID:19306108 Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase; 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form the disaccharide unit of chondroitin-4-sulfate (C4S).
GO:0009986 cell surface	ISS GO_REF:0000024	ACCEPT	Summary: This is an ISS (Inferred from Sequence Similarity) annotation for cell surface localization, based on orthology to rat ARSB (P50430). This reinforces the IEA annotation for cell surface localization. Reason: This annotation is based on manual curation with sequence similarity to rat ARSB and represents higher quality evidence than pure IEA. Combined with the literature evidence for extra-lysosomal membrane localization of ARSB, this annotation should be retained. Supporting Evidence: file:human/ARSB/ARSB-deep-research-perplexity-lite.md Extra-lysosomal: Immunohistochemistry and immunofluorescence studies have also detected ARSB at the cell membrane of hepatocytes, sinusoidal endothelial cells, Kupffer cells, and the apical membranes of colonic and prostatic epithelial cells. file:human/ARSB/ARSB-uniprot.txt SUBCELLULAR LOCATION: Lysosome. Cell surface.
GO:0010632 regulation of epithelial cell migration	IMP PMID:19306108 Arylsulfatase B regulates colonic epithelial cell migration ...	ACCEPT	Summary: This experimental annotation (IMP - Inferred from Mutant Phenotype) demonstrates that ARSB regulates epithelial cell migration. The study showed that silencing or overexpressing ARSB had inverse effects on colonic epithelial cell migration. Reason: This is high-quality experimental evidence showing that ARSB regulates epithelial cell migration through its effects on chondroitin sulfate content, MMP9 expression, and RhoA activation. While this is more of a regulatory role than the core enzymatic function, it represents an important biological function of ARSB and should be retained. Supporting Evidence: PMID:19306108 When ASB expression was silenced by siRNA in the NCM460 cells, [...] cell migration increased * 52%. Following overexpression of ASB, [...] cell migration decreased * 37%. These findings demonstrate marked effects of ASB expression on the migratory activity of colonic epithelial cells file:human/ARSB/ARSB-uniprot.txt Involved in the regulation of cell adhesion, cell migration and invasion in colonic epithelium
GO:0010976 positive regulation of neuron projection development	ISS GO_REF:0000024	KEEP AS NON CORE	Summary: This is an ISS annotation for positive regulation of neuron projection development, based on rat ortholog. This duplicates the IEA annotation for the same term but with manual curation evidence. Reason: This ISS annotation provides stronger evidence than the IEA annotation for the same term. As discussed previously, this represents a non-core, tissue-specific function of ARSB in the nervous system. The annotation should be retained but marked as non-core. Supporting Evidence: file:human/ARSB/ARSB-uniprot.txt In the central nervous system, is a regulator of neurite outgrowth and neuronal plasticity, acting through the control of sulfate glycosaminoglycans and neurocan levels (By similarity).
GO:0061580 colon epithelial cell migration	IMP PMID:19306108 Arylsulfatase B regulates colonic epithelial cell migration ...	ACCEPT	Summary: This experimental annotation (IMP) demonstrates that ARSB affects colon epithelial cell migration specifically. This is a more specific term than the general "regulation of epithelial cell migration" annotation. Reason: This is high-quality experimental evidence for a specific tissue type (colon) and represents an important biological function of ARSB. While more specific than the general epithelial cell migration term, this level of specificity is valuable and should be retained as it reflects the actual experimental system used. Supporting Evidence: PMID:19306108 In the T84 cell line, derived from lung metastasis of malignant colonic epithelial cells, [...] In the T84 cells, matrix metalloproteinase 9 (MMP9), activated RhoA, and cell migration, as well as C4S content, were significantly more than in the NCM460 cells. Silencing and overexpression of ASB had inverse effects on MMP9, activated RhoA, and cell migration
GO:0070062 extracellular exosome	HDA PMID:23533145 In-depth proteomic analyses of exosomes isolated from expres...	KEEP AS NON CORE	Summary: This annotation indicates ARSB is found in extracellular exosomes, based on high-throughput detection assay (HDA) from a proteomic study of exosomes in urine. Reason: This annotation is based on proteomic detection of ARSB in exosomes. While this is a legitimate localization, it represents a non-core aspect of ARSB biology. Many proteins can be found in exosomes, and this may reflect secretion or release mechanisms rather than a primary functional localization. The annotation should be retained as it is experimentally supported, but marked as non-core. Supporting Evidence: PMID:23533145 In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine [ARSB was detected in exosomes]
GO:0005788 endoplasmic reticulum lumen	TAS Reactome:R-HSA-1614362	KEEP AS NON CORE	Summary: This annotation places ARSB in the ER lumen, based on Reactome pathway for SUMF1-mediated oxidation of cysteine to formylglycine. This post-translational modification occurs in the ER during ARSB biosynthesis. Reason: This annotation reflects a transient localization during ARSB biosynthesis and maturation, not the functional localization. The formylglycine modification by SUMF1 occurs in the ER, after which ARSB is trafficked to lysosomes. This should be retained as it reflects an important aspect of ARSB biology (the post-translational modification required for activity), but marked as non-core since it is a biosynthetic intermediate. Supporting Evidence: Reactome:R-HSA-1614362 SUMF1 mediates the oxidation of cysteine to formylglycine, producing active arylsulfatases file:human/ARSB/ARSB-uniprot.txt PTM: The conversion to 3-oxoalanine (also known as C-formylglycine, FGly), of a serine or cysteine residue in prokaryotes and of a cysteine residue in eukaryotes, is critical for catalytic activity.
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-1606789	ACCEPT	Summary: This is another TAS annotation for lysosomal lumen from Reactome pathway "ARSB hydrolyses DS". This is a third annotation for the same GO term from a different Reactome pathway. Reason: This reinforces the lysosomal lumen localization through another Reactome pathway focused on dermatan sulfate degradation. While duplicate, multiple annotations from different pathways strengthen the evidence. Supporting Evidence: Reactome:R-HSA-1606789 Arylsulfatase B (ARSB) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate units
GO:0043202 lysosomal lumen	TAS Reactome:R-HSA-1793207	ACCEPT	Summary: This is a fourth TAS annotation for lysosomal lumen from Reactome pathway "ARSB hydrolyses C4S/C6S chains". This is yet another duplicate from a different pathway. Reason: This reinforces the lysosomal lumen localization through the chondroitin sulfate degradation pathway. Multiple pathway annotations strengthen the evidence for this core localization. Supporting Evidence: Reactome:R-HSA-1793207 Arylsulfatase B using calcium cofactor (ARSB:Ca2+) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate) units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
GO:0004065 arylsulfatase activity	TAS PMID:2303452 Phylogenetic conservation of arylsulfatases. cDNA cloning an...	ACCEPT	Summary: This is a TAS (Traceable Author Statement) annotation for arylsulfatase activity from the seminal 1990 paper that cloned and characterized human ARSB. This provides experimental literature support for the arylsulfatase classification. Reason: This is a foundational reference for ARSB characterization and provides strong experimental support for the arylsulfatase activity annotation. This should definitely be retained as it represents the original biochemical characterization of the enzyme. Supporting Evidence: PMID:2303452 Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B. [...] Overexpression of ASB in transfected baby hamster kidney (BHK) cells resulted in up to 68-fold higher ASB activity
GO:0005764 lysosome	TAS PMID:2303452 Phylogenetic conservation of arylsulfatases. cDNA cloning an...	ACCEPT	Summary: This is a TAS annotation for lysosome localization from the same foundational 1990 paper. This provides experimental literature support for the lysosomal localization. Reason: This is strong experimental evidence from the original characterization of ARSB showing its lysosomal localization and mannose-6-phosphate receptor-mediated trafficking. This is core evidence that should definitely be retained. Supporting Evidence: PMID:2303452 The 47-kDa ASB form was located in dense lysosomes. Transport of ASB to the lysosomes was accomplished in a mannose 6-phosphate receptor-dependent manner.
GO:0007040 lysosome organization	TAS PMID:1718978 Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An inter...	REMOVE	Summary: This annotation suggests ARSB is involved in lysosome organization. The reference is to a 1991 paper about MPS VI mutations, which describes the disease phenotype but does not directly demonstrate that ARSB organizes lysosomes. Reason: This appears to be a misannotation. While ARSB deficiency leads to lysosomal storage disease (MPS VI), this does not mean ARSB's primary function is to organize lysosomes. ARSB is a lysosomal enzyme that degrades glycosaminoglycans; its absence causes substrate accumulation and lysosomal dysfunction, but this is a consequence of enzyme deficiency, not evidence that ARSB actively organizes lysosomes. This annotation should be removed. Supporting Evidence: PMID:1718978 The Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI) is a lysosomal storage disease with autosomal recessive inheritance caused by deficiency of the enzyme arylsulfatase B
GO:0007041 lysosomal transport	TAS PMID:2303452 Phylogenetic conservation of arylsulfatases. cDNA cloning an...	REMOVE	Summary: This annotation suggests ARSB is involved in lysosomal transport. The reference describes ARSB being transported TO lysosomes via the mannose-6-phosphate receptor pathway, not that ARSB performs transport functions. Reason: This is a misannotation. The reference describes ARSB as a cargo being transported to lysosomes, not as performing transport functions. ARSB is a lysosomal enzyme that degrades substrates; it does not transport materials. This annotation confuses the trafficking of ARSB to lysosomes with ARSB having a transport function. This should be removed. Supporting Evidence: PMID:2303452 Transport of ASB to the lysosomes was accomplished in a mannose 6-phosphate receptor-dependent manner
GO:0030209 dermatan sulfate proteoglycan catabolic process	TAS Reactome:R-HSA-1606789	NEW	Summary: ARSB is directly involved in dermatan sulfate degradation by removing 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues. This is one of the primary catabolic pathways in which ARSB participates, as documented in Reactome and the cyberian deep research. Reason: This biological process annotation is missing from the existing GOA file but is a core function of ARSB. Dermatan sulfate is one of two primary substrates for ARSB, and its degradation is blocked in MPS VI patients. This annotation is well-supported by Reactome pathway documentation and literature. Supporting Evidence: Reactome:R-HSA-1606789 Arylsulfatase B (ARSB) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS; Gorham & Cantz 1978) file:human/ARSB/ARSB-deep-research-cyberian.md ARSB acts specifically on two major sulfated glycosaminoglycans: Dermatan sulfate (DS): A heteropolysaccharide composed of repeating disaccharide units containing iduronic acid and N-acetylgalactosamine-4-sulfate file:human/ARSB/ARSB-uniprot.txt Hydrolysis of the 4-sulfate groups of the N-acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and dermatan sulfate.
GO:0006027 glycosaminoglycan catabolic process	TAS Reactome:R-HSA-1606789	NEW	Summary: ARSB participates in the broader glycosaminoglycan catabolic process through its specific role in degrading dermatan sulfate and chondroitin-4-sulfate. This is the parent process that encompasses the more specific DS and C4S catabolic activities. Reason: This biological process annotation represents the broader catabolic category encompassing ARSB function. While more general than the specific dermatan sulfate or chondroitin sulfate proteoglycan catabolic processes, it appropriately captures ARSB's role in GAG catabolism. The annotation is supported by Reactome pathway documentation and literature. Supporting Evidence: Reactome:R-HSA-1606789 Defects in ARSB are the cause of mucopolysaccharidosis type VI (MPSVI) (MIM:253200, also called Maroteaux-Lamy syndrome file:human/ARSB/ARSB-deep-research-cyberian.md ARSB functions within the lysosomal catabolism pathway for sulfated glycosaminoglycans. The sequential degradation of dermatan sulfate and chondroitin sulfate requires multiple enzymes acting in a specific order. file:human/ARSB/ARSB-uniprot.txt DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans

Core Functions

Hydrolyzing 4-sulfate groups from N-acetylgalactosamine residues within dermatan sulfate and chondroitin-4-sulfate glycosaminoglycan chains in the lysosomal lumen

Molecular Function:

N-acetylgalactosamine-4-sulfatase activity

Directly Involved In:

dermatan sulfate proteoglycan catabolic process chondroitin sulfate proteoglycan catabolic process glycosaminoglycan catabolic process

Cellular Locations:

lysosomal lumen

Substrates:

dermatan sulfate chondroitin 4'-sulfate

Supporting Evidence:

PMID:19306108
Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase; 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form the disaccharide unit of chondroitin-4-sulfate (C4S).
PMID:18285341
The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze sulfate groups of CS.
Reactome:R-HSA-1606789
Arylsulfatase B (ARSB) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS)
Reactome:R-HSA-1793207
Arylsulfatase B using calcium cofactor (ARSB:Ca2+) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate) units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
PMID:2303452
The 47-kDa ASB form was located in dense lysosomes. Transport of ASB to the lysosomes was accomplished in a mannose 6-phosphate receptor-dependent manner.
file:human/ARSB/ARSB-uniprot.txt
COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds 1 Ca(2+) ion per subunit.
file:human/ARSB/ARSB-deep-research-cyberian.md
The crystal structure of human ARSB (PDB: 1FSU), solved at 2.5 A resolution, revealed that: Formylglycine (FGly91) is found in a sulfate-modified form (oxo-alanine sulfate ester) in the active site; A divalent calcium ion (Ca2+) is coordinated at the active site and is essential for catalysis
file:human/ARSB/ARSB-deep-research-cyberian.md
The sulfate hydrolysis mechanism proceeds through either an addition-hydrolysis (AH) or transesterification-elimination (TE) pathway, with current evidence favoring the TE mechanism.

References

GO_REF:0000003

Gene Ontology annotation based on Enzyme Commission mapping

GO_REF:0000024

Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity.

GO_REF:0000033

Annotation inferences using phylogenetic trees

GO_REF:0000043

Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping

GO_REF:0000044

Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt.

GO_REF:0000107

Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara.

GO_REF:0000117

Electronic Gene Ontology annotations created by ARBA machine learning models

GO_REF:0000120

Combined Automated Annotation using Multiple IEA Methods.

PMID:1718978

Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.

The G137V mutation in ARSB severely reduces stability of the precursor protein

"The G137V mutation did not affect the synthesis but severely reduced the stability of the arylsulfatase B precursor."
Most of the mutant precursor is degraded before reaching lysosomes

"the majority of the mutant precursor was degraded presumably in a compartment proximal to the trans Golgi network and only a small amount escaped to the lysosomes"
This mutation causes an intermediate form of MPS VI

"accounting for the low residual enzyme activity in fibroblasts of a patient with the juvenile form of the disease."

PMID:18285341

Distinct effects of N-acetylgalactosamine-4-sulfatase and galactose-6-sulfatase expression on chondroitin sulfates.

ARSB (N-acetylgalactosamine-4-sulfatase) hydrolyzes sulfate groups from chondroitin sulfate

"The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze sulfate groups of CS."
Silencing ARSB increases chondroitin-4-sulfate, total chondroitin sulfate, and total sulfated GAG content

"Following silencing of ASB or GALNS, total sGAG, C4S, and CS increased significantly."
Overexpressing ARSB decreases chondroitin-4-sulfate and total chondroitin sulfate

"Following overexpression of ASB or GALNS, total sGAG, C4S, and CS declined significantly."
ARSB expression affects proteoglycan core protein expression (syndecan-1, decorin)

"mRNA expression of core proteins of the CS-containing proteoglycans, syndecan-1 and decorin, was significantly up-regulated following overexpression of ASB"

PMID:19306108

Arylsulfatase B regulates colonic epithelial cell migration by effects on MMP9 expression and RhoA activation.

ARSB removes 4-sulfate groups from N-acetylgalactosamine 4-sulfate in chondroitin-4-sulfate

"Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase; 4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form the disaccharide unit of chondroitin-4-sulfate (C4S)."
ARSB activity is significantly lower in malignant T84 colonic cells compared to normal colonocytes

"In the T84 cell line, derived from lung metastasis of malignant colonic epithelial cells, the activity of ASB, as well as steroid sulfatase, arylsulfatase A, and galactose-6-sulfatase, were significantly less than in normal, primary colonic epithelial cells"
Silencing ARSB increases MMP9 secretion, activated RhoA, and cell migration

"When ASB expression was silenced by siRNA in the NCM460 cells, MMP9 secretion increased to over 3 times the basal level, activated RhoA increased * 85%, and cell migration increased * 52%."
Overexpressing ARSB decreases MMP9, activated RhoA, and cell migration

"Following overexpression of ASB, MMP9 declined 51%, activated RhoA declined * 51%, and cell migration decreased * 37%."
ARSB regulates invasive phenotype of colonic epithelial cells through effects on chondroitin sulfation

"These findings demonstrate marked effects of ASB expression on the migratory activity of colonic epithelial cells, activated RhoA, and MMP9, and suggest a potential vital role of ASB, due to its impact on chondroitin sulfation, on determination of the invasive phenotype of colonic epithelial cells."

PMID:2303452

Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B.

Human ARSB is a 533 amino acid protein with a 41 amino acid signal peptide

"The deduced amino acid sequence of 533 amino acids contains a 41-amino acid N-terminal signal peptide and a mature polypeptide of 492 amino acid residues."
ARSB is synthesized as a 64-kDa precursor and processed to a 47-kDa mature form

"Pulse-chase labeling showed that ASB was synthesized and secreted as a 64-kDa precursor and processed to a 47-kDa mature form in BHK cells."
ARSB localizes to dense lysosomes via mannose-6-phosphate receptor-dependent trafficking

"The 47-kDa ASB form was located in dense lysosomes. Transport of ASB to the lysosomes was accomplished in a mannose 6-phosphate receptor-dependent manner."
ARSB is a member of the arylsulfatase gene family showing phylogenetic conservation

"Deduced amino acid sequences of human arylsulfatase A, human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and an arylsulfatase from sea urchin showed a substantial degree of similarity suggesting that they arose from a common ancestral gene and are members of an arylsulfatase gene family."

PMID:23533145

In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine.

ARSB was detected in exosomes from prostatic secretions by proteomic analysis

"In pooled EPS-urine exosome samples, ~900 proteins were detected [including ARSB]"

Reactome:R-HSA-1606789

ARSB hydrolyses DS

ARSB hydrolyzes sulfate from N-acetylgalactosamine 4-sulfate units within dermatan sulfate

"Arylsulfatase B (ARSB) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS; Gorham & Cantz 1978)"
Conversion of cysteine to 3-oxoalanine (formylglycine) is critical for catalytic activity

"The conversion to 3-oxoalanine (formylglycine, FGly) of a cysteine residue in eukaryotes, is critical for catalytic activity"
Defects in ARSB cause mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)

"Defects in ARSB are the cause of mucopolysaccharidosis type VI (MPSVI) (MIM:253200, also called Maroteaux-Lamy syndrome (Wicker et al. 1991)"

Reactome:R-HSA-1614362

SUMF1 mediates the oxidation of cysteine to formylglycine, producing active arylsulfatases

SUMF1 performs post-translational modification of ARSB required for activity

"SUMF1 mediates the oxidation of cysteine to formylglycine, producing active arylsulfatases"
This modification occurs during ARSB biosynthesis

"SUMF1 mediates the oxidation of cysteine to formylglycine, producing active arylsulfatases [during biosynthesis]"

Reactome:R-HSA-1793207

ARSB hydrolyses C4S/C6S chains

ARSB with calcium cofactor hydrolyzes sulfate from N-acetylgalactosamine 4-sulfate or 6-sulfate units in chondroitin sulfate

"Arylsulfatase B using calcium cofactor (ARSB:Ca2+) hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate) units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate"
Formylglycine modification is critical for catalytic activity

"The conversion to 3-oxoalanine (formylglycine, FGly) of a cysteine residue in eukaryotes, is critical for catalytic activity, based on similarity to the prototypical arylsulfatase ARSA"

Reactome:R-HSA-2282889

Defective ARSB does not hydrolyse C4S/C6S chains

Loss of ARSB function prevents degradation of chondroitin sulfate chains

"Defective ARSB does not hydrolyse C4S/C6S chains"
This leads to MPS VI pathology

"Defective ARSB does not hydrolyse C4S/C6S chains [leading to MPS VI]"

Reactome:R-HSA-6798751

Exocytosis of azurophil granule lumen proteins

ARSB is present in azurophil granules of neutrophils

"Exocytosis of azurophil granule lumen proteins"
These granules can undergo exocytosis, releasing ARSB extracellularly

"Exocytosis of azurophil granule lumen proteins"

Reactome:R-HSA-6800434

Exocytosis of ficolin-rich granule lumen proteins

ARSB is present in ficolin-1-rich granules

"Exocytosis of ficolin-rich granule lumen proteins [ARSB is present]"
These specialized neutrophil granules can release ARSB through exocytosis

"Exocytosis of ficolin-rich granule lumen proteins"

Reactome:R-HSA-9036065

Defective ARSB does not hydrolyse DS

Loss of ARSB function prevents degradation of dermatan sulfate

"Defective ARSB does not hydrolyse DS"
This contributes to MPS VI pathology

"Defective ARSB does not hydrolyse DS [contributing to MPS VI pathology]"

file:human/ARSB/ARSB-uniprot.txt

UniProt entry for ARSB (P15848)

ARSB removes sulfate groups from chondroitin-4-sulfate and regulates its degradation

"Removes sulfate groups from chondroitin-4-sulfate (C4S) and regulates its degradation"
Involved in regulation of cell adhesion, cell migration, and invasion in colonic epithelium

"Involved in the regulation of cell adhesion, cell migration and invasion in colonic epithelium"
Regulates neurite outgrowth and neuronal plasticity in CNS through control of sulfate GAGs and neurocan

"In the central nervous system, is a regulator of neurite outgrowth and neuronal plasticity, acting through the control of sulfate glycosaminoglycans and neurocan levels"
Requires calcium cofactor (binds 1 Ca2+ per subunit)

"COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds 1 Ca(2+) ion per subunit."
Conversion of Cys-91 to 3-oxoalanine (formylglycine) is critical for catalytic activity

"The conversion to 3-oxoalanine (also known as C-formylglycine, FGly), of a serine or cysteine residue in prokaryotes and of a cysteine residue in eukaryotes, is critical for catalytic activity."
Deficiency causes mucopolysaccharidosis type VI (MPS VI)

"DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans"

file:human/ARSB/ARSB-deep-research-perplexity-lite.md

Deep research on ARSB gene

ARSB is predominantly a lysosomal enzyme with extra-lysosomal localization at cell membranes in some cell types

"Primary: ARSB is predominantly a lysosomal enzyme. Extra-lysosomal: Immunohistochemistry and immunofluorescence studies have also detected ARSB at the cell membrane"
ARSB regulates extracellular matrix remodeling, cell migration, and signaling pathways

"Extracellular matrix remodeling: ARSB influences the composition and turnover of the extracellular matrix, affecting cell adhesion, migration, and invasion"
ARSB has tumor suppressor activity; reduced expression linked to cancer progression

"Cancer: Reduced ARSB expression is linked to altered proteoglycan expression and tumor progression in prostate and colonic epithelial cells. Acts as a tumor suppressor"
ARSB regulates neuronal development through control of sulfated GAGs and neurocan

"Neuronal development: In the central nervous system, ARSB regulates neurite outgrowth and neuronal plasticity by controlling sulfate GAG and neurocan levels"
Enzyme replacement therapy with recombinant ARSB is standard treatment for MPS VI

"Enzyme replacement therapy (ERT) with recombinant ARSB is the standard treatment for MPS VI, aiming to reduce GAG accumulation and ameliorate symptoms"

file:human/ARSB/ARSB-deep-research-cyberian.md

Deep research on ARSB gene (cyberian)

ARSB catalyzes removal of 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues at the non-reducing end of GAG chains

"Arylsulfatase B (ARSB) is a sulfohydrolase that catalyzes the removal of 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues located at the non-reducing end of glycosaminoglycan (GAG) chains. The systematic name of the enzyme is N-acetyl-D-galactosamine-4-sulfate 4-sulfohydrolase (Bond et al., 1997; Valayannopoulos et al., 2010)."
ARSB also demonstrates activity against N-acetylglucosamine-4-sulfate as a substrate

"Notably, ARSB also demonstrates activity against N-acetylglucosamine-4-sulfate as a substrate (Bond et al., 1997). This activity is consistent with the enzyme's ability to act on related 4-sulfated hexosamine residues, though its primary physiological substrates remain the GAG chains of DS and C4S."
Formylglycine (FGly91) is found in a sulfate-modified form at the active site, and calcium ion is essential for catalysis

"The crystal structure of human ARSB (PDB: 1FSU), solved at 2.5 A resolution, revealed that: Formylglycine (FGly91) is found in a sulfate-modified form (oxo-alanine sulfate ester) in the active site; A divalent calcium ion (Ca2+) is coordinated at the active site and is essential for catalysis; The calcium ion binds directly to the sulfate group of the modified cysteine residue (Bond et al., 1997)"
Sulfate hydrolysis proceeds through transesterification-elimination (TE) mechanism

"The sulfate hydrolysis mechanism proceeds through either an addition-hydrolysis (AH) or transesterification-elimination (TE) pathway, with current evidence favoring the TE mechanism. In this mechanism: The aldehyde of formylglycine becomes hydrated to a gem-diol; One hydroxyl of the gem-diol attacks the substrate sulfur, forming a covalent enzyme-sulfate intermediate; Elimination releases the product and regenerates the aldehyde (Hanson et al., 2004)"
ARSB is targeted to lysosomes via the mannose-6-phosphate (M6P) receptor pathway

"The mature enzyme of 533 amino acids is generated after cleavage of the signal peptide and is targeted to lysosomes via the mannose-6-phosphate (M6P) receptor pathway (Braulke & Bonifacino, 2009)."
ARSB participates in extracellular GAG remodeling at the plasma membrane and in the extracellular matrix

"While primarily a lysosomal enzyme, ARSB also exhibits extra-lysosomal localization. Studies have demonstrated ARSB presence at the plasma membrane and in the extracellular matrix, where it participates in local GAG remodeling (Bhattacharyya et al., 2009)."
ARSB modulates galectin-3 binding and SHP-2 phosphatase activity through control of chondroitin sulfation

"Beyond its housekeeping role in GAG catabolism, ARSB has emerged as a regulator of cellular signaling and gene expression. By controlling the sulfation status of cell-surface and extracellular GAGs, ARSB modulates: Galectin-3 binding: The degree of chondroitin 4-sulfation affects galectin-3 sequestration and release, influencing downstream signaling; SHP-2 phosphatase activity: ARSB activity impacts SHP-2 localization and function (Bhattacharyya et al., 2022)"
ARSB functions as a tumor suppressor, transcriptional mediator, and regulator of cellular signaling

"These broader roles suggest ARSB functions as a tumor suppressor, transcriptional mediator, and regulator of cellular signaling beyond its classical lysosomal function."
The ARSB protein structure contains an active site domain resembling alkaline phosphatase

"Despite lacking detectable sequence similarity, the ARSB active site domain closely resembles that of alkaline phosphatase. The calcium in ARSB superimposes on one of the zinc ions in alkaline phosphatase, and the oxo-alanine sulfate ester superimposes on the phosphate ion in alkaline phosphatase (Bond et al., 1997)"
Over 220 unique ARSB variants have been identified causing MPS VI

"Genetic heterogeneity: Over 220 unique ARSB variants have been identified, including Missense variants: 59.5%, Small deletions: 13.5%, Nonsense mutations: 12.0%, Splice site variants: 5.0%"

Deep Research

Cyberian

(ARSB-deep-research-cyberian.md)

Comprehensive Research Report: ARSB (Arylsulfatase B) Cyberian deep-research 5 citations 2026-01-15T17:06:46.500681

Comprehensive Research Report: ARSB (Arylsulfatase B)

Gene/Protein Identity Verification

UniProt Accession: P15848
Protein Names: Arylsulfatase B (ASB); N-acetylgalactosamine-4-sulfatase (G4S)
EC Number: 3.1.6.12
Gene Symbol: ARSB
Chromosomal Location: 5q14.1
Organism: Homo sapiens (Human)
Protein Family: Sulfatase family
Key Domains: Sulfatase_N (IPR000917), Sulfatase (PF00884), Alkaline_phosphatase_core_sf (IPR017850)

The identity of ARSB has been unambiguously verified through multiple authoritative databases and extensive primary literature. ARSB encodes a lysosomal sulfatase enzyme whose deficiency causes the well-characterized lysosomal storage disorder Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

1. Enzymatic Function and Catalytic Mechanism

1.1 Reaction Catalyzed

Arylsulfatase B (ARSB) is a sulfohydrolase that catalyzes the removal of 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues located at the non-reducing end of glycosaminoglycan (GAG) chains. The systematic name of the enzyme is N-acetyl-D-galactosamine-4-sulfate 4-sulfohydrolase (Bond et al., 1997; Valayannopoulos et al., 2010).

The reaction catalyzed is:

N-acetyl-D-galactosamine-4-sulfate + H2O → N-acetyl-D-galactosamine + sulfate

This hydrolytic cleavage of the sulfate ester bond is essential for the sequential degradation of the glycosaminoglycans dermatan sulfate (DS) and chondroitin 4-sulfate (C4S) within lysosomes (Tomatsu et al., 2021).

1.2 Substrate Specificity

ARSB acts specifically on two major sulfated glycosaminoglycans:

Dermatan sulfate (DS): A heteropolysaccharide composed of repeating disaccharide units containing iduronic acid and N-acetylgalactosamine-4-sulfate
Chondroitin 4-sulfate (C4S): A related glycosaminoglycan containing glucuronic acid instead of iduronic acid

The enzyme exhibits strict positional specificity, exclusively hydrolyzing the 4-O-sulfate ester bond on N-acetylgalactosamine residues. Notably, ARSB also demonstrates activity against N-acetylglucosamine-4-sulfate as a substrate (Bond et al., 1997). This activity is consistent with the enzyme's ability to act on related 4-sulfated hexosamine residues, though its primary physiological substrates remain the GAG chains of DS and C4S.

1.3 Catalytic Mechanism and Active Site

The catalytic mechanism of ARSB requires a unique post-translational modification: the conversion of a critical cysteine residue (Cys91) to formylglycine (3-oxoalanine or FGly). This modification is catalyzed by the formylglycine-generating enzyme (FGE/SUMF1) and is essential for activity of all type I sulfatases (Dierks et al., 2003; Preusser-Kunze et al., 2005).

The crystal structure of human ARSB (PDB: 1FSU), solved at 2.5 Å resolution, revealed that:

Formylglycine (FGly91) is found in a sulfate-modified form (oxo-alanine sulfate ester) in the active site
A divalent calcium ion (Ca²⁺) is coordinated at the active site and is essential for catalysis
The calcium ion binds directly to the sulfate group of the modified cysteine residue (Bond et al., 1997)

The sulfate hydrolysis mechanism proceeds through either an addition-hydrolysis (AH) or transesterification-elimination (TE) pathway, with current evidence favoring the TE mechanism. In this mechanism:

The aldehyde of formylglycine becomes hydrated to a gem-diol
One hydroxyl of the gem-diol attacks the substrate sulfur, forming a covalent enzyme-sulfate intermediate
Elimination releases the product and regenerates the aldehyde (Hanson et al., 2004)

The requirement for molecular oxygen in the formation of formylglycine explains why sulfatase activity is oxygen-dependent during enzyme biosynthesis.

2. Subcellular Localization

2.1 Lysosomal Targeting

ARSB is synthesized as a precursor protein containing a signal peptide that directs it to the endoplasmic reticulum (ER). The mature enzyme of 533 amino acids is generated after cleavage of the signal peptide and is targeted to lysosomes via the mannose-6-phosphate (M6P) receptor pathway (Braulke & Bonifacino, 2009).

The lysosomal targeting mechanism involves:

N-glycosylation: ARSB undergoes N-linked glycosylation in the ER
Phosphorylation: In the cis-Golgi network, the enzyme UDP-N-acetylglucosamine 1-phosphotransferase recognizes lysosomal hydrolases and adds N-acetylglucosamine-1-phosphate to specific mannose residues
M6P tag generation: A second enzyme removes the N-acetylglucosamine, exposing the mannose-6-phosphate recognition marker
Receptor binding: In the trans-Golgi network, ARSB binds to either the cation-independent M6P receptor (CI-MPR, ~300 kDa) or the cation-dependent M6P receptor (CD-MPR, ~46 kDa)
Delivery: The receptor-enzyme complexes are transported to late endosomes/lysosomes via clathrin-coated vesicles, where the acidic pH induces dissociation (Ghosh et al., 2003)

2.2 Extracellular Localization

While primarily a lysosomal enzyme, ARSB also exhibits extra-lysosomal localization. Studies have demonstrated ARSB presence at the plasma membrane and in the extracellular matrix, where it participates in local GAG remodeling (Bhattacharyya et al., 2009). This extra-lysosomal activity appears particularly important for:

Regulation of chondroitin sulfate proteoglycan turnover in the extracellular matrix
Modulation of cell signaling through control of sulfated GAG-protein interactions

The enzyme can also be secreted and recaptured by cells via the M6P receptor pathway, a phenomenon that forms the basis of enzyme replacement therapy (Sly et al., 1978).

3. Biological Processes and Pathways

3.1 Glycosaminoglycan Degradation Pathway

ARSB functions within the lysosomal catabolism pathway for sulfated glycosaminoglycans. The sequential degradation of dermatan sulfate and chondroitin sulfate requires multiple enzymes acting in a specific order, as each enzyme is strictly substrate-specific and there is no functional redundancy (Coutinho et al., 2012).

The degradation sequence for dermatan sulfate involves:

Endolytic cleavage: Hyaluronidases (particularly HYAL1 and HYAL4) initially cleave the GAG polymer into oligosaccharides
Exolytic processing: Sequential removal of terminal residues by specific exoenzymes:
Iduronate-2-sulfatase (IDS): Removes 2-O-sulfate from iduronic acid residues
α-L-iduronidase (IDUA): Cleaves unsulfated iduronic acid
ARSB: Removes 4-O-sulfate from N-acetylgalactosamine
β-hexosaminidase: Cleaves N-acetylgalactosamine

For chondroitin 4-sulfate, the pathway is similar but involves glucuronidase instead of iduronidase for uronic acid cleavage.

The blockade of this pathway at the ARSB step results in accumulation of partially degraded dermatan sulfate and chondroitin 4-sulfate within lysosomes, leading to cellular dysfunction and the clinical manifestations of MPS VI (Valayannopoulos et al., 2010).

3.2 Tissue-Specific GAG Accumulation

Importantly, even within MPS VI, GAG accumulation shows tissue-specific patterns:

Hepatocytes: Approximately 80% of accumulated GAGs are iduronate-rich dermatan sulfate
Bone and kidney cells: Up to 90% of accumulated GAGs are glucuronate-rich chondroitin sulfate (Montaño et al., 2007)

This differential accumulation suggests that abnormal chondroitin sulfate metabolism plays a particularly important role in the skeletal manifestations of MPS VI.

3.3 Broader Regulatory Functions

Beyond its housekeeping role in GAG catabolism, ARSB has emerged as a regulator of cellular signaling and gene expression. By controlling the sulfation status of cell-surface and extracellular GAGs, ARSB modulates:

Galectin-3 binding: The degree of chondroitin 4-sulfation affects galectin-3 sequestration and release, influencing downstream signaling
SHP-2 phosphatase activity: ARSB activity impacts SHP-2 localization and function
Wnt/β-catenin signaling: Through effects on chondroitin sulfate proteoglycans
Transcriptional regulation: ARSB-mediated changes in chondroitin sulfation influence transcription factor activity and chromatin remodeling (Bhattacharyya et al., 2022)

These broader roles suggest ARSB functions as a tumor suppressor, transcriptional mediator, and regulator of cellular signaling beyond its classical lysosomal function.

4. Structural Biology

4.1 Gene and Protein Structure

The human ARSB gene is located on chromosome 5q14.1, spans approximately 208 kb, and contains 8 exons. The full-length transcript of 4,852 bp encodes a precursor protein that is processed to the mature 533-amino acid enzyme (Tomatsu et al., 2021).

The ARSB protein consists of two domains:

Large N-terminal domain: Contains the active site and belongs to the α/β class of proteins. This domain features a 10-stranded mixed β-sheet flanked by α-helices. The active site is located in a cleft at the C-terminal end of this large β-sheet.
Smaller C-terminal domain: Contributes to overall protein stability

4.2 Crystal Structure

The crystal structure of human ARSB (PDB: 1FSU) provided critical insights into sulfatase catalysis. Key structural features include:

Active site: The catalytic site contains 10 conserved amino acid residues, including the critical Cys91 modified to 3-oxoalanine (formylglycine)
Metal ion: A calcium ion is coordinated at the active site and is essential for catalysis
Structural homology: Despite lacking detectable sequence similarity, the ARSB active site domain closely resembles that of alkaline phosphatase. The calcium in ARSB superimposes on one of the zinc ions in alkaline phosphatase, and the oxo-alanine sulfate ester superimposes on the phosphate ion in alkaline phosphatase (Bond et al., 1997)

Additional structural studies with vanadate-inhibited ARSB showed that vanadate replaces sulfate at the active site and forms a covalent linkage to the protein, providing insight into the reaction mechanism.

4.3 Post-Translational Modifications

The essential post-translational modification of Cys91 to formylglycine is catalyzed by the formylglycine-generating enzyme (FGE), encoded by the SUMF1 gene. This modification:

Is absolutely required for catalytic activity
Occurs in the endoplasmic reticulum before ARSB reaches lysosomes
Involves oxidation of the cysteine thiol to an aldehyde in a molecular oxygen-dependent reaction
Requires a conserved sequence motif (CXPXR) surrounding the target cysteine (Dierks et al., 2005)

Deficiency of FGE/SUMF1 results in Multiple Sulfatase Deficiency (MSD), where all sulfatases including ARSB show reduced activity.

5. Disease Associations

5.1 Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome)

ARSB deficiency causes Mucopolysaccharidosis Type VI, an autosomal recessive lysosomal storage disorder first described in 1963. The disease has a prevalence of 0.36-1.3 per 100,000 live births across different populations (Tomatsu et al., 2021).

Genetic heterogeneity: Over 220 unique ARSB variants have been identified, including:
- Missense variants: 59.5%
- Small deletions: 13.5%
- Nonsense mutations: 12.0%
- Splice site variants: 5.0%

The substantial genetic heterogeneity (with ~32% of variants reported only once) limits genotype-phenotype correlations.

Clinical phenotypes:

Rapidly progressing form:
Presents before age 2
Severe skeletal involvement
Adult height typically <120 cm
Features: claw hands, facial dysmorphism, kyphosis, cardiorespiratory insufficiency
Slowly progressing form:
Normal or mildly coarsened facial features
Delayed diagnosis (average age 23.5 years)
Initial presentation with joint stiffness/pain

Notably, MPS VI does not affect cognitive function, distinguishing it from other mucopolysaccharidoses.

Pathophysiology: The lack of ARSB activity leads to progressive accumulation of dermatan sulfate and chondroitin 4-sulfate in lysosomes, causing:
- Cellular enlargement and organomegaly
- Inflammation and tissue damage
- Secondary disruption of lysosomal function
- Progressive atrophy of affected tissues

5.2 Therapeutic Approaches

Enzyme Replacement Therapy (ERT):
Galsulfase (Naglazyme), a recombinant human ARSB, was approved by the FDA in 2005. It is administered as weekly intravenous infusions at 1.0 mg/kg. The therapeutic mechanism relies on the M6P receptor-mediated secretion-recapture pathway to deliver exogenous enzyme to cells.

Clinical benefits include:
- Significant reduction in urinary GAG levels
- Improved endurance and joint mobility
- Stabilized cardiac function
- Enhanced survival when initiated before age 5

Limitations include poor efficacy against skeletal manifestations, corneal clouding, and cardiac valve pathology due to poor vascularization of these tissues.

Emerging therapies:
- Gene therapy: AAV2/8-mediated ARSB gene transfer shows promise with stable enzyme expression for >1 year
- Substrate reduction therapy: Odiparcil reduces GAG synthesis to decrease substrate burden
- Combination approaches: Anti-inflammatory agents (infliximab, pentosan polysulfate) combined with ERT

6. Conclusions

ARSB (Arylsulfatase B) is a well-characterized lysosomal sulfatase that plays an essential role in glycosaminoglycan catabolism. The enzyme specifically removes 4-O-sulfate groups from N-acetylgalactosamine-4-sulfate residues at the non-reducing ends of dermatan sulfate and chondroitin 4-sulfate chains, enabling their sequential degradation. ARSB requires a unique formylglycine post-translational modification for catalytic activity, utilizes a calcium ion at its active site, and is targeted to lysosomes via the mannose-6-phosphate receptor pathway.

Deficiency of ARSB causes Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome), a progressive storage disorder affecting multiple organ systems. The availability of enzyme replacement therapy has improved outcomes for patients, though significant unmet medical need remains, particularly for skeletal and corneal manifestations. Beyond its classical role in lysosomal catabolism, emerging evidence suggests ARSB participates in cellular signaling regulation through control of extracellular GAG sulfation status.

References

Bhattacharyya S, et al. (2009). Cell-bound IL-8 increases in bronchial epithelial cells after arylsulfatase B silencing due to sequestration with chondroitin-4-sulfate. Am J Respir Cell Mol Biol. 42(1):51-61.
Bhattacharyya S, et al. (2022). Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases. Int J Mol Sci. 23(21):13146.
Bond CS, et al. (1997). Structure of a human lysosomal sulfatase. Structure. 5(2):277-89. [PDB: 1FSU]
Braulke T, Bonifacino JS. (2009). Sorting of lysosomal proteins. Biochim Biophys Acta. 1793(4):684-93.
Coutinho MF, et al. (2012). Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012:471325.
Dierks T, et al. (2003). Multiple sulfatase deficiency is caused by mutations in the gene encoding the human Cα-formylglycine generating enzyme. Cell. 113(4):435-44.
Dierks T, et al. (2005). Molecular basis for multiple sulfatase deficiency and mechanism for formylglycine generation of the human formylglycine-generating enzyme. Cell. 121(4):541-52.
Ghosh P, et al. (2003). Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol. 4(3):202-12.
Hanson SR, et al. (2004). Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed. 43(43):5736-63.
Montaño AM, et al. (2007). Mucopolysaccharidosis IVA: characterization of a common mutation found in British Columbia, Canada. Hum Mutat. 28(6):550.
Preusser-Kunze A, et al. (2005). Molecular characterization of the human Cα-formylglycine-generating enzyme. J Biol Chem. 280(15):14900-10.
Sly WS, et al. (1978). Enzyme replacement in Hunter and Hurler disease: uptake of native enzyme by cultivated fibroblasts. Birth Defects Orig Artic Ser. 14(6B):283-94.
Tomatsu S, et al. (2021). Mucopolysaccharidosis Type VI, an Updated Overview of the Disease. Int J Mol Sci. 22(24):13456.
Valayannopoulos V, et al. (2010). Mucopolysaccharidosis VI. Orphanet J Rare Dis. 5:5.

Online Resources Consulted

Citations

bhattacharyya_2022_broader_roles.md
bond_1997_structure.md
coutinho_2012_gag_disorders.md
dierks_2003_sumf1.md
tomatsu_2021_mpsvi_review.md

Falcon

(ARSB-deep-research-falcon.md)

this with annotations you find in gene/protein databases, but these can be outdated or inaccurate. Falcon Edison Scientific Literature 25 citations 2025-12-26T10:32:10.787115

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human ARSB (UniProt P15848)

Executive summary

Verified identity: ARSB encodes human arylsulfatase B (N‑acetylgalactosamine‑4‑sulfatase), a lysosomal sulfatase (EC 3.1.6.12) that removes the 4‑O‑sulfate from N‑acetylgalactosamine‑4‑sulfate residues at the non‑reducing ends of dermatan sulfate and chondroitin‑4‑sulfate. Catalysis requires a Cα‑formylglycine (FGly) cofactor generated by SUMF1. ARSB is synthesized with a signal peptide, N‑glycosylated, mannose‑6‑phosphate (M6P)–tagged, and trafficked via the M6P receptor to lysosomes, with reported extra‑lysosomal localization. Deficiency causes mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy). (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5, stapletonbradley2020screeningandtreatments pages 206-211)
Clinical implementations: Enzyme replacement therapy (ERT) with galsulfase (Naglazyme) is approved for MPS VI, supported by 2024 consensus recommendations and real‑world pharmacovigilance (2005–2023 FAERS). Access and multidisciplinary care remain critical system needs. (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5, li2024realworldpharmacovigilanceanalysis pages 1-2)

Key concepts and definitions (current understanding)

Molecular identity and family: ARSB is a human lysosomal sulfatase in the broader alkaline phosphatase/sulfatase superfamily; the ARSB gene maps to 5q14.1. The enzyme was historically identified as the ARSB activity deficient in MPS VI. (Tobacman & Bhattacharyya 2022; DOI: https://doi.org/10.3390/ijms232113146) (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30)
Enzymatic reaction and specificity: ARSB catalyzes hydrolysis of the 4‑O‑sulfate at the non‑reducing end of N‑acetylgalactosamine‑4‑sulfate, acting on dermatan sulfate and chondroitin‑4‑sulfate in glycosaminoglycan (GAG) catabolism; activity is often assayed with nitrocatechol sulfate/4‑methylumbelliferyl sulfate. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 2-5)
Catalytic cofactor and activation: The catalytic cysteine (e.g., Cys91) is post‑translationally converted to Cα‑formylglycine (FGly) by the formylglycine‑generating enzyme encoded by SUMF1, a requirement shared across sulfatases and central to the pathobiology of multiple sulfatase deficiency. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30)
Maturation and targeting: ARSB is synthesized with an N‑terminal signal peptide, undergoes N‑glycosylation and M6P tagging, and is delivered to lysosomes via M6P receptors, where proteolytic maturation yields the active enzyme. Mechanistic background on M6P trafficking and sulfatase maturation is established in the lysosome literature. (Stapleton‑Bradley dissertation 2020; DOI: https://doi.org/10.58088/kwzy-g903) (stapletonbradley2020screeningandtreatments pages 206-211)
Localization: Canonically lysosomal; extra‑lysosomal localization at cell surface and nucleus has been reported in human epithelia and other tissues, suggesting roles beyond classical lysosomal catabolism. (tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)
Disease definition: ARSB deficiency causes MPS VI (Maroteaux–Lamy), a lysosomal storage disorder with dermatan/chondroitin‑4‑sulfate accumulation; SUMF1 defects cause multiple sulfatase deficiency that secondarily impairs ARSB activation. (tobacman2022profoundimpactof pages 16-17, tobacman2022profoundimpactof pages 27-29)

Human ARSB (arylsulfatase B; EC 3.1.6.12) is a member of the sulfatase family that functions as an exo‑sulfohydrolase.
It catalyzes hydrolysis of the 4‑O‑sulfate at the non‑reducing terminus of N‑acetylgalactosamine‑4‑sulfate residues in dermatan sulfate and chondroitin‑4‑sulfate.
Catalysis requires a Cα‑formylglycine at the active‑site cysteine, generated post‑translationally by the formylglycine‑generating enzyme encoded by SUMF1 (FGE).
ARSB is synthesized with an N‑terminal signal peptide, undergoes N‑linked glycosylation and mannose‑6‑phosphate modification, and is trafficked via M6P receptors to lysosomes where it is proteolytically matured.
While its canonical residence and function are lysosomal in glycosaminoglycan catabolism, extra‑lysosomal localization at the cell surface and in nuclei has been reported.
Loss of ARSB activity causes accumulation of dermatan sulfate and chondroitin‑4‑sulfate, producing mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome), and defective SUMF1 can create a multiple sulfatase deficiency context that impairs ARSB activation.
Because ARSB‑mediated desulfation alters glycosaminoglycan structure, ARSB activity influences extracellular‑matrix interactions and cell signaling beyond classical lysosomal storage pathology.

Blockquote: Concise, citable summary of ARSB identity, reaction, maturation/trafficking, localization, pathway role, and disease relevance for use in the full report (sources: Tobacman et al. 2022 review and lysosomal trafficking background) (tobacman2022profoundimpactof pages 1-2, stapletonbradley2020screeningandtreatments pages 206-211).

Recent developments and latest research (emphasis 2023–2024)

Consensus recommendations for MPS VI (2024): A national Delphi‑style expert panel (Saudi Arabia) issued management recommendations for MPS VI, emphasizing immediate initiation of ERT (galsulfase) upon diagnosis, establishment of multidisciplinary care teams, individualized follow‑up, and system‑level actions (centers of excellence, national registries, reimbursement programs). Limitations of current ERT (e.g., weekly infusions, limited impact on ocular/skeletal/established cardiac disease) and the need for home‑infusion pathways are highlighted (Orphanet J Rare Dis, Jul 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
Real‑world safety of galsulfase (2005–2023 FAERS, published 2024): A pharmacovigilance analysis of 20,281,876 FAERS reports identified 3,195 galsulfase‑associated AEs; signal detection across four algorithms found 27 affected organ systems (notably respiratory and infections). Median AE onset was 1,471 days with over half within five years. Newly signaled urologic AEs (e.g., membranous glomerulonephritis, nephritic syndrome) underscore the need for continued surveillance (Frontiers in Pharmacology, Aug 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
Burden and quality of life (China, 2019 survey; published 2024): In a cross‑sectional survey (n=180; includes MPS VI cases) diagnostic delay averaged 9.42 months; only 6.67% were diagnosed at the first visit; patients averaged 6.31 visits and 4.3 hospitals before diagnosis. Direct medical costs during the diagnostic period averaged ¥81,086.72 (63.75% of total). Only 32.78% had received specific treatments; HRQoL (PedsQL/SF‑36) was significantly lower than population norms, with household income, treatment, and subtype associated with HRQoL (Orphanet J Rare Dis, Sep 2024; https://doi.org/10.1186/s13023-024-03333-4). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8)
Mechanistic breadth (2022–2024): Reviews and preclinical reports continue to detail ARSB’s regulation of cell‑signaling via changes in chondroitin‑4‑sulfate sulfation and binding partners, plus extra‑lysosomal localizations in human tissues; these support expanding biological roles beyond classical storage pathology. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)

Current applications and real‑world implementations

Enzyme replacement therapy (ERT): Galsulfase is the approved recombinant human ARSB for MPS VI. Clinical consensus emphasizes early initiation and structured, multidisciplinary follow‑up, with selective use of home‑infusion programs to improve adherence and access (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
Pharmacovigilance in practice: FAERS data through Q4 2023 provide real‑world AE profiles and onset timing for galsulfase—supporting risk communication, monitoring plans, and hypothesis generation for rare, off‑label, or long‑latency events (Frontiers in Pharmacology 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
Health systems and access: National‑level recommendations and burden studies identify the need for centers of excellence, registries, and reimbursement mechanisms to reduce diagnostic delay and improve equitable ERT access. China’s national rare‑disease network (since 2019) illustrates system‑level responses to these needs (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03333-4; Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8, alsayed2024consensusbasedexpertrecommendations pages 9-11)

Expert opinions and authoritative analysis

National expert consensus: The 2024 Saudi consensus provides structured recommendations for MPS VI care delivery, including early ERT, multidisciplinary management, and system‑level reforms, reflecting authoritative, context‑adapted clinical guidance (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
Mechanistic reviews: ARSB’s core biochemistry, SUMF1‑dependent activation, and expanding physiological roles are reviewed with synthesis across human and model data, supporting the canonical lysosomal catabolic function and extra‑lysosomal activities (IJMS 2022; https://doi.org/10.3390/ijms232113146). (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5)

Relevant statistics and data (recent studies)

Galsulfase AE profile (FAERS 2005–2023): 3,195 galsulfase‑associated AE reports; 27 organ systems implicated; median AE onset 1,471 days; over half within five years; new urologic signals observed—publication Aug 2024 (Frontiers in Pharmacology; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
Diagnostic journey and costs (China, published 2024): Mean diagnostic delay 9.42 months; 6.67% diagnosed at first visit; average 6.31 visits/4.3 hospitals before diagnosis; mean direct medical costs during diagnosis ¥81,086.72 (63.75% of total); only 32.78% received specific treatments; HRQoL significantly below norms (Orphanet J Rare Dis; https://doi.org/10.1186/s13023-024-03333-4). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8)

Detailed functional annotation of ARSB

Reaction and pathway: ARSB is an exo‑sulfohydrolase that removes terminal 4‑O‑sulfate from GalNAc‑4‑sulfate residues in dermatan sulfate/chondroitin‑4‑sulfate, a late step in lysosomal GAG breakdown. Deficiency elevates C4S/DS storage, driving MPS VI pathology in cartilage, connective tissues, and viscera. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 16-17)
Subcellular localization: Predominantly lysosomal via M6P‑guided trafficking; extra‑lysosomal localizations (cell surface, nucleus) have been reported in human epithelium, liver, and other tissues, suggesting signaling effects through altered GAG sulfation in microdomains. (tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)
Maturation and cofactor biology: SUMF1‑dependent FGly generation is essential for catalysis; defects in SUMF1 produce multiple sulfatase deficiency with broad loss of sulfatase activities including ARSB. M6P receptor–mediated sorting and proteolytic maturation complete activation and lysosomal deployment. (tobacman2022profoundimpactof pages 29-30, stapletonbradley2020screeningandtreatments pages 206-211)

Clinical relevance and therapy landscape

MPS VI (Maroteaux–Lamy): ARSB mutations cause MPS VI; disease burden includes progressive skeletal dysplasia, cardiopulmonary disease, ophthalmic involvement, and systemic manifestations. ERT with galsulfase improves endurance, pulmonary function, and global symptoms, though limitations exist for skeletal/ocular/established cardiac disease. Early initiation and coordinated multidisciplinary care are advised. (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3) (alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
Safety and monitoring: Long‑term pharmacovigilance indicates multi‑system AEs and emerging signals, reinforcing the need for structured monitoring programs and registry‑based follow‑up (Frontiers in Pharmacology 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
Health systems perspective: Real‑world data emphasize substantial diagnostic delays, financial burden, and under‑utilization of specific therapies, motivating national networks, reimbursement schemes, and home‑infusion options to improve outcomes and equity (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03333-4; https://doi.org/10.1186/s13023-024-03237-3). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8, alsayed2024consensusbasedexpertrecommendations pages 9-11)

Verification of gene/protein identity and ambiguity check

The ARSB symbol corresponds to human arylsulfatase B (N‑acetylgalactosamine‑4‑sulfatase; UniProt P15848), a lysosomal sulfatase. Literature cited above consistently studies human ARSB and the human disease MPS VI; no conflicting use of the symbol for a different gene/protein in another organism was found in the evidence set used here. Domain/family assignment (sulfatase) and required FGly modification align with sulfatase family characteristics. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5)

References and source metadata

Tobacman JK, Bhattacharyya S. Profound impact of decline in N‑acetylgalactosamine‑4‑sulfatase (Arylsulfatase B) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences. Published Oct 2022. URL: https://doi.org/10.3390/ijms232113146 (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31, tobacman2022profoundimpactof pages 16-17, tobacman2022profoundimpactof pages 27-29, tobacman2022profoundimpactof pages 2-5)
AlSayed M, et al. Consensus‑based expert recommendations on the management of MPS IVa and VI in Saudi Arabia. Orphanet Journal of Rare Diseases. Published Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3 (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
Li S, et al. Real‑world pharmacovigilance analysis of galsulfase (FAERS 2005–2023). Frontiers in Pharmacology. Published Aug 2024. URL: https://doi.org/10.3389/fphar.2024.1420126 (li2024realworldpharmacovigilanceanalysis pages 1-2)
Kang Q, et al. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China. Orphanet Journal of Rare Diseases. Published Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4 (kang2024healthserviceutilization pages 6-8, kang2024healthserviceutilization pages 1-2)
Stapleton‑Bradley M. Screening and treatments for the mucopolysaccharidoses (dissertation). University of Delaware. Published 2020. URL: https://doi.org/10.58088/kwzy-g903 (stapletonbradley2020screeningandtreatments pages 206-211)

Limitations

Some mechanistic background on lysosomal targeting and M6P trafficking is derived from established literature summarized in a dissertation source in the evidence set; readers should refer to primary lysosome/M6P receptor reviews for additional mechanistic detail. (stapletonbradley2020screeningandtreatments pages 206-211)

References

(tobacman2022profoundimpactof pages 1-2): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 29-30): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 2-5): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(stapletonbradley2020screeningandtreatments pages 206-211): Molly Stapleton-Bradley. Screening and treatments for the mucopolysaccharidoses. Dissertation, 2020. URL: https://doi.org/10.58088/kwzy-g903, doi:10.58088/kwzy-g903. This article has 0 citations.
(alsayed2024consensusbasedexpertrecommendations pages 9-11): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.
(alsayed2024consensusbasedexpertrecommendations pages 2-4): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.
(alsayed2024consensusbasedexpertrecommendations pages 4-5): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.
(li2024realworldpharmacovigilanceanalysis pages 1-2): Shangze Li, Runcheng Huang, Yuanyuan Meng, Yijia Liu, Jiao Qian, Junjie Zou, and Jun Yang. Real-world pharmacovigilance analysis of galsulfase: a study based on the fda adverse event reporting system (faers) database. Frontiers in Pharmacology, Aug 2024. URL: https://doi.org/10.3389/fphar.2024.1420126, doi:10.3389/fphar.2024.1420126. This article has 2 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 23-25): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 30-31): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 16-17): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(tobacman2022profoundimpactof pages 27-29): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.
(kang2024healthserviceutilization pages 1-2): Qi Kang, Yuhang Fang, Yan Yang, Dingguo Li, Lin Zheng, Xinyi Chen, Xiaowen Tu, and Chunlin Jin. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in china. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4, doi:10.1186/s13023-024-03333-4. This article has 9 citations and is from a peer-reviewed journal.
(kang2024healthserviceutilization pages 6-8): Qi Kang, Yuhang Fang, Yan Yang, Dingguo Li, Lin Zheng, Xinyi Chen, Xiaowen Tu, and Chunlin Jin. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in china. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4, doi:10.1186/s13023-024-03333-4. This article has 9 citations and is from a peer-reviewed journal.

Citations

stapletonbradley2020screeningandtreatments pages 206-211
li2024realworldpharmacovigilanceanalysis pages 1-2
tobacman2022profoundimpactof pages 1-2
tobacman2022profoundimpactof pages 29-30
tobacman2022profoundimpactof pages 2-5
alsayed2024consensusbasedexpertrecommendations pages 9-11
alsayed2024consensusbasedexpertrecommendations pages 2-4
alsayed2024consensusbasedexpertrecommendations pages 4-5
tobacman2022profoundimpactof pages 23-25
tobacman2022profoundimpactof pages 30-31
tobacman2022profoundimpactof pages 16-17
tobacman2022profoundimpactof pages 27-29
kang2024healthserviceutilization pages 1-2
kang2024healthserviceutilization pages 6-8
https://doi.org/10.3390/ijms232113146
https://doi.org/10.58088/kwzy-g903
https://doi.org/10.1186/s13023-024-03237-3
https://doi.org/10.3389/fphar.2024.1420126
https://doi.org/10.1186/s13023-024-03333-4
https://doi.org/10.1186/s13023-024-03333-4;
https://doi.org/10.3390/ijms232113146,
https://doi.org/10.58088/kwzy-g903,
https://doi.org/10.1186/s13023-024-03237-3,
https://doi.org/10.3389/fphar.2024.1420126,
https://doi.org/10.1186/s13023-024-03333-4,

Perplexity

(ARSB-deep-research-perplexity-lite.md)

**Key Concepts and Definitions** Perplexity sonar-pro 9 citations 2025-11-15T18:18:49.160449

The ARSB (arylsulfatase B) gene encodes a lysosomal enzyme essential for the degradation of specific glycosaminoglycans (GAGs), with broad implications for cellular metabolism, signaling, and human disease[1][2][3][6][8].

Key Concepts and Definitions

Molecular Function:
ARSB encodes the enzyme N-acetylgalactosamine-4-sulfatase, which hydrolyzes (removes) 4-sulfate groups from the GAGs dermatan sulfate and chondroitin-4-sulfate[1][2][3][6][8]. This activity is classified as sulfuric ester hydrolase activity and is critical for the stepwise degradation of these GAGs in lysosomes[3][6][8].
Biological Processes:
Lysosomal degradation of GAGs: ARSB is central to the catabolism of dermatan sulfate and chondroitin sulfate, preventing their accumulation[1][2][3][6][8].
Extracellular matrix remodeling: ARSB influences the composition and turnover of the extracellular matrix, affecting cell adhesion, migration, and invasion[1][3][8].
Cell signaling: ARSB modulates signaling pathways, including those involving inflammatory mediators (e.g., interleukin-8), and impacts RhoA activation and matrix metalloproteinase secretion[1].
Neuronal development: In the central nervous system, ARSB regulates neurite outgrowth and neuronal plasticity by controlling sulfate GAG and neurocan levels[3][6][8].
Cellular Localization:
Primary: ARSB is predominantly a lysosomal enzyme[1][2][3][4][6][8].
Extra-lysosomal: Immunohistochemistry and immunofluorescence studies have also detected ARSB at the cell membrane of hepatocytes, sinusoidal endothelial cells, Kupffer cells, and the apical membranes of colonic and prostatic epithelial cells[4]. Membrane localization is reduced in malignant tissues[4].

Protein Domains and Structure

Protein Family: ARSB belongs to the sulfatase family[1][3][6][8].
Domain Structure:
The enzyme is a homodimer[1][3].
Contains a sulfatase domain responsible for its catalytic activity[8].
The active site includes a formylglycine residue, essential for catalysis, generated by post-translational modification[6][8].
Isoforms: Two alternatively spliced transcript variants encoding distinct isoforms have been identified[1][3].

Known Interactions

Protein-Protein Interactions:
ARSB interacts with galectin-3, influencing the expression of the proteoglycan versican via AP-1-mediated transcription[5].
Reduced ARSB activity increases galectin-3 binding to less-sulfated chondroitin-4-sulfate, affecting transcription factors (AP-1, SP-1) and downstream targets (e.g., WNT9A, GPNMB)[4][5].
ARSB deficiency leads to increased binding of SHP2 to more-sulfated chondroitin-4-sulfate, activating signaling pathways (p38, MITF)[4].
Pathway Involvement:
ARSB is involved in glycosaminoglycan metabolism and sphingolipid metabolism[3].

Disease Associations

Mucopolysaccharidosis Type VI (MPS VI, Maroteaux–Lamy syndrome):
Cause: Autosomal recessive deficiency of ARSB leads to lysosomal accumulation of dermatan sulfate and chondroitin sulfate[1][2][3][4][6].
Clinical Features: Multi-system involvement, including skeletal, cardiac, and ocular abnormalities, organomegaly, and progressive tissue damage[1][2][3].
Cancer:
Reduced ARSB expression is linked to altered proteoglycan expression and tumor progression in prostate and colonic epithelial cells[1][4].
Acts as a tumor suppressor; silencing ARSB increases galectin-3 and promotes oncogenic signaling[4].
Cystic Fibrosis:
ARSB activity is modulated by the cystic fibrosis transmembrane conductance regulator (CFTR), with implications for disease pathology[4].
Atherosclerosis-related Stroke:
Emerging evidence suggests a role for ARSB in promoting atherosclerosis-related stroke, warranting further investigation[7].
Metachromatic Leukodystrophy:
ARSB is also associated with this lysosomal storage disorder, though less commonly than MPS VI[3].

Recent Developments and Research (2023–2024)

Therapeutic Approaches:
Enzyme replacement therapy (ERT) with recombinant ARSB is the standard treatment for MPS VI, aiming to reduce GAG accumulation and ameliorate symptoms[1].
Research is ongoing into gene therapy and small-molecule approaches to enhance ARSB activity or delivery, including targeting extra-lysosomal pools for tissue-specific effects[1].
Cancer and Metabolism:
Recent studies highlight ARSB’s role in tumor suppression and metabolic regulation, including effects on aerobic glycolysis and mitochondrial function in cancer cells[4].
Tissue Engineering:
ARSB is being explored for its potential to modify extracellular matrix composition and support tissue recovery after injury[1].

Relevant Statistics and Data

Functional Associations:
ARSB has over 6,400 functional associations with biological entities across molecular, cellular, and disease categories, as extracted from 106 datasets[1].
Expression:
ARSB is expressed in multiple tissues, with highest levels in the liver, pancreas, and kidneys[4].

Expert Opinions and Analysis

Central Role in Lysosomal Homeostasis:
Experts emphasize ARSB’s indispensable function in lysosomal GAG degradation and its broader impact on cell signaling and tissue architecture[1][2][3][6][8].
Therapeutic Target:
ARSB is a validated target for enzyme replacement in MPS VI and is under investigation for broader applications in cancer and tissue engineering[1][4].

Citations (with URLs and Dates where available):

Ma’ayan Lab Harmonizome, ARSB gene (2024)
MedlinePlus Genetics, ARSB gene (2024)
GeneCards, ARSB (2024)
Wikipedia, Arylsulfatase B (2024)
NCBI Gene, ARSB (2024)
UniProt, ARSB_HUMAN (P15848) (2024)
NCBI Gene, ARSB (2024)
InterPro, Arylsulfatase B (P15848) (2024)
Human Protein Atlas, ARSB (2024)

Citations

https://maayanlab.cloud/Harmonizome/gene/ARSB
https://medlineplus.gov/genetics/gene/arsb/
https://www.genecards.org/cgi-bin/carddisp.pl?gene=ARSB
https://en.wikipedia.org/wiki/Arylsulfatase_B
https://www.ncbi.nlm.nih.gov/gene/411
https://www.uniprot.org/uniprotkb/P15848/entry
https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=411
https://www.ebi.ac.uk/interpro/protein/reviewed/P15848
https://www.proteinatlas.org/ENSG00000113273-ARSB/structure+interaction

📄 View Raw YAML

id: P15848
gene_symbol: ARSB
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: Arylsulfatase B (ARSB) is a lysosomal enzyme that catalyzes the
  hydrolysis of 4-sulfate groups from N-acetylgalactosamine residues within
  chondroitin-4-sulfate and dermatan sulfate. This sulfatase activity is
  essential for the ordered degradation of glycosaminoglycans in lysosomes.
  Deficiency of ARSB leads to mucopolysaccharidosis type VI (Maroteaux-Lamy
  syndrome), characterized by accumulation of dermatan sulfate and chondroitin
  sulfate. Beyond its lysosomal role, ARSB regulates extracellular matrix
  composition, cell migration, and signaling pathways by controlling sulfation
  patterns of glycosaminoglycans.
existing_annotations:
- term:
    id: GO:0008484
    label: sulfuric ester hydrolase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: This IBA annotation correctly identifies ARSB as a sulfuric ester
      hydrolase, which is accurate as ARSB catalyzes hydrolysis of sulfate ester
      bonds. This is the broader enzymatic class encompassing the more specific
      N-acetylgalactosamine-4-sulfatase activity. The phylogenetic evidence
      supporting this annotation is strong across mammalian orthologs.
    action: ACCEPT
    reason: This is an appropriate molecular function term that accurately
      reflects the core catalytic activity of ARSB. While more general than the
      specific N-acetylgalactosamine-4-sulfatase activity, it correctly places
      ARSB in the sulfatase family. The IBA evidence based on phylogenetic
      conservation is robust.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: Deduced amino acid sequences of human arylsulfatase A,
        human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and
        an arylsulfatase from sea urchin showed a substantial degree of
        similarity suggesting that they arose from a common ancestral gene and
        are members of an arylsulfatase gene family.
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'RecName: Full=Arylsulfatase B; Short=ASB; EC=3.1.6.12'
    - reference_id: file:human/ARSB/ARSB-deep-research-falcon.md
      supporting_text: See deep research file for comprehensive analysis
- term:
    id: GO:0003943
    label: N-acetylgalactosamine-4-sulfatase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000003
  review:
    summary: This annotation correctly identifies the specific enzymatic
      activity of ARSB. The EC mapping (EC:3.1.6.12) accurately reflects that
      ARSB catalyzes the hydrolysis of 4-sulfate groups from
      N-acetylgalactosamine residues in both chondroitin sulfate and dermatan
      sulfate. This is the primary and most specific molecular function of ARSB.
    action: ACCEPT
    reason: This is the most precise molecular function term for ARSB and should
      be retained as a core annotation. Although this is IEA based on EC
      mapping, it is also supported by multiple experimental studies (IDA
      annotations from PMID:18285341 and PMID:19306108).
    supported_by:
    - reference_id: PMID:18285341
      supporting_text: The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase
        (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze
        sulfate groups of CS.
    - reference_id: PMID:19306108
      supporting_text: Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase;
        4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from
        N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form
        the disaccharide unit of chondroitin-4-sulfate (C4S).
    - reference_id: Reactome:R-HSA-1793207
      supporting_text: Arylsulfatase B using calcium cofactor (ARSB:Ca2+)
        hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate)
        units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
- term:
    id: GO:0004065
    label: arylsulfatase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  review:
    summary: This annotation identifies ARSB as having arylsulfatase activity,
      which is a broader classification than the specific
      N-acetylgalactosamine-4-sulfatase activity. While technically correct,
      this term is somewhat less informative than GO:0003943.
    action: ACCEPT
    reason: This annotation is correct and reflects the arylsulfatase family
      membership of ARSB. Although broader than the specific sulfatase activity,
      it is appropriate to retain this alongside the more specific term, as it
      reflects the historical nomenclature and biochemical classification. This
      is also supported by a TAS annotation.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: Phylogenetic conservation of arylsulfatases. cDNA cloning
        and expression of human arylsulfatase B. [...] members of an
        arylsulfatase gene family.
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'RecName: Full=Arylsulfatase B'
- term:
    id: GO:0005764
    label: lysosome
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  review:
    summary: This annotation correctly places ARSB in the lysosome, which is the
      primary and well-established cellular compartment where ARSB functions.
      ARSB is a classical lysosomal enzyme that degrades glycosaminoglycans in
      this organelle.
    action: ACCEPT
    reason: This is a core cellular component annotation for ARSB. The lysosomal
      localization is extensively documented and is the primary site of ARSB
      function in glycosaminoglycan degradation. This is supported by both IEA
      and TAS evidence, as well as the original biochemical characterization of
      the enzyme.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: The 47-kDa ASB form was located in dense lysosomes.
        Transport of ASB to the lysosomes was accomplished in a mannose
        6-phosphate receptor-dependent manner.
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome'
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: 'Primary: ARSB is predominantly a lysosomal enzyme'
- term:
    id: GO:0008484
    label: sulfuric ester hydrolase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: This is a duplicate annotation of the IBA sulfuric ester hydrolase
      activity annotation (line 2 of GOA file), but with different evidence (IEA
      from combined automated methods) and ortholog mapping to rat ARSB.
    action: ACCEPT
    reason: While this is a duplicate GO term, it represents independent
      evidence from automated orthology mapping, which reinforces the IBA
      annotation. It is acceptable to have the same term with different evidence
      codes.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: Deduced amino acid sequences of human arylsulfatase A,
        human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and
        an arylsulfatase from sea urchin showed a substantial degree of
        similarity
- term:
    id: GO:0009986
    label: cell surface
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: This annotation indicates ARSB localizes to the cell surface. While
      ARSB is primarily lysosomal, there is evidence from UniProt and literature
      that ARSB can be detected at the cell membrane in certain cell types,
      particularly in colonic and prostatic epithelial cells. This
      extra-lysosomal localization may have functional significance.
    action: ACCEPT
    reason: Although ARSB is predominantly a lysosomal enzyme, the evidence for
      cell surface localization should not be dismissed. The deep research
      document notes that ARSB has been detected at cell membranes, and this may
      represent a non-core but biologically relevant localization. There is also
      an ISS annotation supporting this.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: 'Extra-lysosomal: Immunohistochemistry and immunofluorescence
        studies have also detected ARSB at the cell membrane of hepatocytes, sinusoidal
        endothelial cells, Kupffer cells, and the apical membranes of colonic and
        prostatic epithelial cells. Membrane localization is reduced in malignant
        tissues.'
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome. Cell surface.'
- term:
    id: GO:0016787
    label: hydrolase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: This is a very broad molecular function term indicating that ARSB
      is a hydrolase, which is technically correct but not informative. This
      term is the parent of more specific terms like sulfuric ester hydrolase
      activity.
    action: ACCEPT
    reason: While this term is extremely broad and not very informative, it is
      technically correct and represents the top-level enzymatic classification.
      It is acceptable to keep this alongside more specific terms, as it may be
      useful for broad queries. However, this is clearly less informative than
      the more specific sulfatase activity terms.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: EC=3.1.6.12 [hydrolase class]
- term:
    id: GO:0046872
    label: metal ion binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: This annotation indicates metal ion binding activity. ARSB requires
      calcium as a cofactor, binding one Ca2+ ion per subunit. The term is
      somewhat generic but is biochemically accurate.
    action: MODIFY
    reason: While ARSB does bind metal ions, specifically calcium, the current
      term is too generic. A more specific term would be calcium ion binding
      (GO:0005509), which accurately reflects the specific metal requirement
      documented in UniProt and Reactome. The current term should be replaced
      with the more specific calcium ion binding term.
    proposed_replacement_terms:
    - id: GO:0005509
      label: calcium ion binding
    supported_by:
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds
        1 Ca(2+) ion per subunit.'
    - reference_id: Reactome:R-HSA-1793207
      supporting_text: Arylsulfatase B using calcium cofactor (ARSB:Ca2+)
        hydrolyses sulfate from N-acetylgalactosamine 4-sulfate
- term:
    id: GO:0006914
    label: autophagy
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation suggests ARSB is involved in autophagy, based on
      orthology to rat ARSB. While ARSB is a lysosomal enzyme and lysosomes are
      involved in autophagy, there is no direct evidence that ARSB specifically
      participates in autophagic processes beyond being a general lysosomal
      enzyme.
    action: REMOVE
    reason: This annotation appears to be an over-annotation. While ARSB is
      lysosomal and lysosomes participate in autophagy, there is no specific
      evidence that ARSB has a direct functional role in autophagy itself.
      ARSB's primary function is glycosaminoglycan degradation, not autophagy
      regulation. This annotation likely arises from guilt-by-association with
      the lysosome rather than a specific biological role.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: ARSB encodes the enzyme
        N-acetylgalactosamine-4-sulfatase, which hydrolyzes (removes) 4-sulfate
        groups from the GAGs dermatan sulfate and chondroitin-4-sulfate [does
        not mention autophagy as a specific function]
- term:
    id: GO:0007584
    label: response to nutrient
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation suggests ARSB is involved in response to nutrient,
      based on orthology to rat. There is no specific evidence that ARSB
      responds to or regulates nutrient sensing beyond its general role as a
      lysosomal enzyme.
    action: REMOVE
    reason: This appears to be an over-annotation without specific supporting
      evidence. While lysosomal function can be influenced by nutrient status,
      there is no indication that ARSB specifically mediates nutrient response
      pathways. This annotation likely reflects general lysosomal biology rather
      than a specific ARSB function.
    supported_by: []
- term:
    id: GO:0009268
    label: response to pH
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation indicates ARSB is involved in response to pH. As a
      lysosomal enzyme, ARSB functions optimally at acidic pH (the lysosomal
      environment), but there is no evidence it specifically responds to or
      regulates pH.
    action: REMOVE
    reason: This is an over-annotation. While ARSB activity is pH-dependent
      (like most lysosomal enzymes that function optimally at acidic pH), this
      does not mean ARSB is involved in pH response as a biological process. The
      term implies ARSB actively participates in sensing or responding to pH
      changes, which is not supported by evidence.
    supported_by: []
- term:
    id: GO:0010976
    label: positive regulation of neuron projection development
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation suggests ARSB positively regulates neuron
      projection development, based on orthology to rat. UniProt states that in
      the central nervous system, ARSB is a regulator of neurite outgrowth and
      neuronal plasticity through control of sulfate glycosaminoglycans and
      neurocan levels, though this is based on similarity evidence.
    action: KEEP_AS_NON_CORE
    reason: While there is supporting evidence from UniProt (based on
      similarity) that ARSB regulates neurite outgrowth in the CNS, this appears
      to be a non-core, tissue-specific function rather than a primary function
      of ARSB. The core function is glycosaminoglycan degradation; the neuronal
      effects are downstream consequences of this activity in neural tissue.
      This should be retained but marked as non-core.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: In the central nervous system, is a regulator of neurite
        outgrowth and neuronal plasticity, acting through the control of sulfate
        glycosaminoglycans and neurocan levels (By similarity).
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: 'Neuronal development: In the central nervous system, ARSB
        regulates neurite outgrowth and neuronal plasticity by controlling sulfate
        GAG and neurocan levels'
- term:
    id: GO:0043627
    label: response to estrogen
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation suggests ARSB is involved in response to estrogen,
      based on orthology to rat. There is no specific evidence in the literature
      or UniProt that ARSB directly responds to or mediates estrogen signaling.
    action: REMOVE
    reason: This appears to be an over-annotation without supporting evidence.
      While ARSB expression levels might be influenced by various factors
      including hormones, there is no specific evidence that ARSB plays a role
      in estrogen response pathways. This annotation should be removed unless
      specific evidence emerges.
    supported_by: []
- term:
    id: GO:0051597
    label: response to methylmercury
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  review:
    summary: This annotation suggests ARSB is involved in response to
      methylmercury, based on orthology to rat. This appears to be an artifact
      of expression studies in rats and does not reflect a specific biological
      function of ARSB.
    action: REMOVE
    reason: This is an over-annotation that likely reflects experimental
      conditions in rat studies rather than a genuine biological function. There
      is no evidence that ARSB has a specific role in methylmercury response or
      detoxification. This should be removed.
    supported_by: []
- term:
    id: GO:0003943
    label: N-acetylgalactosamine-4-sulfatase activity
  evidence_type: IDA
  original_reference_id: PMID:18285341
  review:
    summary: This is experimental (IDA) confirmation of the specific
      N-acetylgalactosamine-4-sulfatase activity of ARSB. The study directly
      demonstrated that ARSB hydrolyzes sulfate groups from chondroitin sulfates
      and that modifying ARSB expression affects chondroitin-4-sulfate levels.
    action: ACCEPT
    reason: This is a gold-standard experimental annotation that directly
      demonstrates the primary molecular function of ARSB. This is core evidence
      supporting the specific enzymatic activity and should definitely be
      retained.
    supported_by:
    - reference_id: PMID:18285341
      supporting_text: The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase
        (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze
        sulfate groups of CS. [...] Following silencing of ASB or GALNS, total
        sGAG, C4S, and CS increased significantly. Following overexpression of
        ASB or GALNS, total sGAG, C4S, and CS declined significantly.
- term:
    id: GO:0030207
    label: chondroitin sulfate proteoglycan catabolic process
  evidence_type: IDA
  original_reference_id: PMID:18285341
  review:
    summary: This experimental annotation indicates ARSB is involved in
      chondroitin sulfate proteoglycan catabolism. The study demonstrated that
      ARSB expression affects the content of chondroitin sulfate and its
      proteoglycans, with overexpression leading to reduced CS and increased
      syndecan-1 and decorin core protein expression.
    action: ACCEPT
    reason: This annotation is well-supported by experimental evidence. The
      study shows that ARSB affects both the glycosaminoglycan chains and the
      proteoglycan content, justifying annotation to the proteoglycan catabolic
      process. ARSB's enzymatic removal of sulfate groups from chondroitin
      sulfate chains is a key step in proteoglycan degradation.
    supported_by:
    - reference_id: PMID:18285341
      supporting_text: Following silencing of ASB or GALNS, total sGAG, C4S, and
        CS increased significantly. Following overexpression of ASB or GALNS,
        total sGAG, C4S, and CS declined significantly.
    - reference_id: PMID:18285341
      supporting_text: mRNA expression of core proteins of the CS-containing
        proteoglycans, syndecan-1 and decorin, was significantly up-regulated
        following overexpression of ASB
- term:
    id: GO:0043202
    label: lysosomal lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-2282889
  review:
    summary: This annotation places ARSB in the lysosomal lumen based on
      Reactome pathway annotation for defective ARSB in MPS VI. The lysosomal
      lumen is indeed where ARSB functions to degrade glycosaminoglycans.
    action: ACCEPT
    reason: This is an accurate and specific cellular component annotation. ARSB
      is a soluble lysosomal enzyme that functions in the lysosomal lumen, where
      it encounters its substrates during glycosaminoglycan degradation. This is
      more specific than just "lysosome" and should be retained.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: The 47-kDa ASB form was located in dense lysosomes.
    - reference_id: Reactome:R-HSA-2282889
      supporting_text: Defective ARSB does not hydrolyse C4S/C6S chains [implies
        ARSB functions in lysosomal lumen]
- term:
    id: GO:0043202
    label: lysosomal lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9036065
  review:
    summary: This is another TAS annotation for lysosomal lumen from a different
      Reactome pathway (defective ARSB not hydrolyzing dermatan sulfate). This
      is a duplicate of the previous annotation but from a different pathway.
    action: ACCEPT
    reason: While this is a duplicate GO term, it represents independent
      evidence from a different Reactome pathway, which reinforces the
      localization. It is acceptable to have the same term with different
      references.
    supported_by:
    - reference_id: Reactome:R-HSA-9036065
      supporting_text: Defective ARSB does not hydrolyse DS
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798751
  review:
    summary: This annotation indicates ARSB is found in the extracellular
      region, specifically in the context of azurophil granule exocytosis from
      neutrophils. ARSB can be secreted and found extracellularly.
    action: KEEP_AS_NON_CORE
    reason: While ARSB is primarily a lysosomal enzyme, it can be secreted and
      found in the extracellular region, particularly during neutrophil
      degranulation. This represents a non-core localization that is
      biologically relevant but secondary to the main lysosomal function. The
      annotation should be retained but marked as non-core.
    supported_by:
    - reference_id: Reactome:R-HSA-6798751
      supporting_text: Exocytosis of azurophil granule lumen proteins [ARSB is
        among the proteins released]
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: ARSB is predominantly a lysosomal enzyme. Extra-lysosomal
        [localizations exist]
- term:
    id: GO:0005576
    label: extracellular region
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6800434
  review:
    summary: This is another annotation for extracellular region from Reactome,
      this time in the context of ficolin-1-rich granule exocytosis. This is a
      duplicate GO term with different supporting evidence.
    action: KEEP_AS_NON_CORE
    reason: This reinforces the extracellular localization through a different
      pathway (ficolin-rich granule exocytosis). As with the previous
      extracellular region annotation, this is a non-core localization but
      should be retained.
    supported_by:
    - reference_id: Reactome:R-HSA-6800434
      supporting_text: Exocytosis of ficolin-rich granule lumen proteins [ARSB
        is among the proteins released]
- term:
    id: GO:0035578
    label: azurophil granule lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6798751
  review:
    summary: This annotation places ARSB in azurophil granule lumen of
      neutrophils. Azurophil granules are specialized secretory granules in
      neutrophils that can contain lysosomal enzymes.
    action: KEEP_AS_NON_CORE
    reason: This is a specialized, cell-type-specific localization of ARSB in
      neutrophils. While accurate, this represents a non-core localization
      specific to neutrophils and their degranulation processes. This should be
      retained as it is supported by Reactome but marked as non-core.
    supported_by:
    - reference_id: Reactome:R-HSA-6798751
      supporting_text: Azurophil granules are generally described as spherical.
        Like lysosomes, they contain CD63 in their membrane (Cham et al. 1994)
        but are regarded as specialized secretory granules rather than lysosomes
        (Cieutat et al. 1998)
- term:
    id: GO:1904813
    label: ficolin-1-rich granule lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6800434
  review:
    summary: This annotation places ARSB in ficolin-1-rich granule lumen,
      another type of secretory granule in neutrophils. This is a very specific,
      cell-type-restricted localization.
    action: KEEP_AS_NON_CORE
    reason: This is an extremely specific cellular compartment in neutrophils.
      While the annotation is supported by Reactome, it represents a highly
      specialized, non-core localization. It should be retained for completeness
      but clearly marked as non-core and cell-type-specific.
    supported_by:
    - reference_id: Reactome:R-HSA-6800434
      supporting_text: Exocytosis of ficolin-rich granule lumen proteins
- term:
    id: GO:0003943
    label: N-acetylgalactosamine-4-sulfatase activity
  evidence_type: IDA
  original_reference_id: PMID:19306108
  review:
    summary: This is another experimental (IDA) confirmation of ARSB's
      N-acetylgalactosamine-4-sulfatase activity from a different study. This
      study demonstrated that modulating ARSB expression affects
      chondroitin-4-sulfate content and related cellular functions.
    action: ACCEPT
    reason: This is independent experimental evidence for the core molecular
      function of ARSB. Having multiple IDA annotations from different studies
      strengthens the evidence for this critical activity. This should
      definitely be retained.
    supported_by:
    - reference_id: PMID:19306108
      supporting_text: Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase;
        4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from
        N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form
        the disaccharide unit of chondroitin-4-sulfate (C4S).
- term:
    id: GO:0009986
    label: cell surface
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: This is an ISS (Inferred from Sequence Similarity) annotation for
      cell surface localization, based on orthology to rat ARSB (P50430). This
      reinforces the IEA annotation for cell surface localization.
    action: ACCEPT
    reason: This annotation is based on manual curation with sequence similarity
      to rat ARSB and represents higher quality evidence than pure IEA. Combined
      with the literature evidence for extra-lysosomal membrane localization of
      ARSB, this annotation should be retained.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
      supporting_text: 'Extra-lysosomal: Immunohistochemistry and immunofluorescence
        studies have also detected ARSB at the cell membrane of hepatocytes, sinusoidal
        endothelial cells, Kupffer cells, and the apical membranes of colonic and
        prostatic epithelial cells.'
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Lysosome. Cell surface.'
- term:
    id: GO:0010632
    label: regulation of epithelial cell migration
  evidence_type: IMP
  original_reference_id: PMID:19306108
  review:
    summary: This experimental annotation (IMP - Inferred from Mutant Phenotype)
      demonstrates that ARSB regulates epithelial cell migration. The study
      showed that silencing or overexpressing ARSB had inverse effects on
      colonic epithelial cell migration.
    action: ACCEPT
    reason: This is high-quality experimental evidence showing that ARSB
      regulates epithelial cell migration through its effects on chondroitin
      sulfate content, MMP9 expression, and RhoA activation. While this is more
      of a regulatory role than the core enzymatic function, it represents an
      important biological function of ARSB and should be retained.
    supported_by:
    - reference_id: PMID:19306108
      supporting_text: When ASB expression was silenced by siRNA in the NCM460
        cells, [...] cell migration increased * 52%. Following overexpression of
        ASB, [...] cell migration decreased * 37%. These findings demonstrate
        marked effects of ASB expression on the migratory activity of colonic
        epithelial cells
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: Involved in the regulation of cell adhesion, cell
        migration and invasion in colonic epithelium
- term:
    id: GO:0010976
    label: positive regulation of neuron projection development
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  review:
    summary: This is an ISS annotation for positive regulation of neuron
      projection development, based on rat ortholog. This duplicates the IEA
      annotation for the same term but with manual curation evidence.
    action: KEEP_AS_NON_CORE
    reason: This ISS annotation provides stronger evidence than the IEA
      annotation for the same term. As discussed previously, this represents a
      non-core, tissue-specific function of ARSB in the nervous system. The
      annotation should be retained but marked as non-core.
    supported_by:
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: In the central nervous system, is a regulator of neurite
        outgrowth and neuronal plasticity, acting through the control of sulfate
        glycosaminoglycans and neurocan levels (By similarity).
- term:
    id: GO:0061580
    label: colon epithelial cell migration
  evidence_type: IMP
  original_reference_id: PMID:19306108
  review:
    summary: This experimental annotation (IMP) demonstrates that ARSB affects
      colon epithelial cell migration specifically. This is a more specific term
      than the general "regulation of epithelial cell migration" annotation.
    action: ACCEPT
    reason: This is high-quality experimental evidence for a specific tissue
      type (colon) and represents an important biological function of ARSB.
      While more specific than the general epithelial cell migration term, this
      level of specificity is valuable and should be retained as it reflects the
      actual experimental system used.
    supported_by:
    - reference_id: PMID:19306108
      supporting_text: In the T84 cell line, derived from lung metastasis of
        malignant colonic epithelial cells, [...] In the T84 cells, matrix
        metalloproteinase 9 (MMP9), activated RhoA, and cell migration, as well
        as C4S content, were significantly more than in the NCM460 cells.
        Silencing and overexpression of ASB had inverse effects on MMP9,
        activated RhoA, and cell migration
- term:
    id: GO:0070062
    label: extracellular exosome
  evidence_type: HDA
  original_reference_id: PMID:23533145
  review:
    summary: This annotation indicates ARSB is found in extracellular exosomes,
      based on high-throughput detection assay (HDA) from a proteomic study of
      exosomes in urine.
    action: KEEP_AS_NON_CORE
    reason: This annotation is based on proteomic detection of ARSB in exosomes.
      While this is a legitimate localization, it represents a non-core aspect
      of ARSB biology. Many proteins can be found in exosomes, and this may
      reflect secretion or release mechanisms rather than a primary functional
      localization. The annotation should be retained as it is experimentally
      supported, but marked as non-core.
    supported_by:
    - reference_id: PMID:23533145
      supporting_text: In-depth proteomic analyses of exosomes isolated from
        expressed prostatic secretions in urine [ARSB was detected in exosomes]
- term:
    id: GO:0005788
    label: endoplasmic reticulum lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1614362
  review:
    summary: This annotation places ARSB in the ER lumen, based on Reactome
      pathway for SUMF1-mediated oxidation of cysteine to formylglycine. This
      post-translational modification occurs in the ER during ARSB biosynthesis.
    action: KEEP_AS_NON_CORE
    reason: This annotation reflects a transient localization during ARSB
      biosynthesis and maturation, not the functional localization. The
      formylglycine modification by SUMF1 occurs in the ER, after which ARSB is
      trafficked to lysosomes. This should be retained as it reflects an
      important aspect of ARSB biology (the post-translational modification
      required for activity), but marked as non-core since it is a biosynthetic
      intermediate.
    supported_by:
    - reference_id: Reactome:R-HSA-1614362
      supporting_text: SUMF1 mediates the oxidation of cysteine to
        formylglycine, producing active arylsulfatases
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'PTM: The conversion to 3-oxoalanine (also known as C-formylglycine,
        FGly), of a serine or cysteine residue in prokaryotes and of a cysteine residue
        in eukaryotes, is critical for catalytic activity.'
- term:
    id: GO:0043202
    label: lysosomal lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1606789
  review:
    summary: This is another TAS annotation for lysosomal lumen from Reactome
      pathway "ARSB hydrolyses DS". This is a third annotation for the same GO
      term from a different Reactome pathway.
    action: ACCEPT
    reason: This reinforces the lysosomal lumen localization through another
      Reactome pathway focused on dermatan sulfate degradation. While duplicate,
      multiple annotations from different pathways strengthen the evidence.
    supported_by:
    - reference_id: Reactome:R-HSA-1606789
      supporting_text: Arylsulfatase B (ARSB) hydrolyses sulfate from
        N-acetylgalactosamine 4-sulfate units
- term:
    id: GO:0043202
    label: lysosomal lumen
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1793207
  review:
    summary: This is a fourth TAS annotation for lysosomal lumen from Reactome
      pathway "ARSB hydrolyses C4S/C6S chains". This is yet another duplicate
      from a different pathway.
    action: ACCEPT
    reason: This reinforces the lysosomal lumen localization through the
      chondroitin sulfate degradation pathway. Multiple pathway annotations
      strengthen the evidence for this core localization.
    supported_by:
    - reference_id: Reactome:R-HSA-1793207
      supporting_text: Arylsulfatase B using calcium cofactor (ARSB:Ca2+)
        hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate)
        units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
- term:
    id: GO:0004065
    label: arylsulfatase activity
  evidence_type: TAS
  original_reference_id: PMID:2303452
  review:
    summary: This is a TAS (Traceable Author Statement) annotation for
      arylsulfatase activity from the seminal 1990 paper that cloned and
      characterized human ARSB. This provides experimental literature support
      for the arylsulfatase classification.
    action: ACCEPT
    reason: This is a foundational reference for ARSB characterization and
      provides strong experimental support for the arylsulfatase activity
      annotation. This should definitely be retained as it represents the
      original biochemical characterization of the enzyme.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: Phylogenetic conservation of arylsulfatases. cDNA cloning
        and expression of human arylsulfatase B. [...] Overexpression of ASB in
        transfected baby hamster kidney (BHK) cells resulted in up to 68-fold
        higher ASB activity
- term:
    id: GO:0005764
    label: lysosome
  evidence_type: TAS
  original_reference_id: PMID:2303452
  review:
    summary: This is a TAS annotation for lysosome localization from the same
      foundational 1990 paper. This provides experimental literature support for
      the lysosomal localization.
    action: ACCEPT
    reason: This is strong experimental evidence from the original
      characterization of ARSB showing its lysosomal localization and
      mannose-6-phosphate receptor-mediated trafficking. This is core evidence
      that should definitely be retained.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: The 47-kDa ASB form was located in dense lysosomes.
        Transport of ASB to the lysosomes was accomplished in a mannose
        6-phosphate receptor-dependent manner.
- term:
    id: GO:0007040
    label: lysosome organization
  evidence_type: TAS
  original_reference_id: PMID:1718978
  review:
    summary: This annotation suggests ARSB is involved in lysosome organization.
      The reference is to a 1991 paper about MPS VI mutations, which describes
      the disease phenotype but does not directly demonstrate that ARSB
      organizes lysosomes.
    action: REMOVE
    reason: This appears to be a misannotation. While ARSB deficiency leads to
      lysosomal storage disease (MPS VI), this does not mean ARSB's primary
      function is to organize lysosomes. ARSB is a lysosomal enzyme that
      degrades glycosaminoglycans; its absence causes substrate accumulation and
      lysosomal dysfunction, but this is a consequence of enzyme deficiency, not
      evidence that ARSB actively organizes lysosomes. This annotation should be
      removed.
    supported_by:
    - reference_id: PMID:1718978
      supporting_text: The Maroteaux-Lamy syndrome (mucopolysaccharidosis type
        VI) is a lysosomal storage disease with autosomal recessive inheritance
        caused by deficiency of the enzyme arylsulfatase B
- term:
    id: GO:0007041
    label: lysosomal transport
  evidence_type: TAS
  original_reference_id: PMID:2303452
  review:
    summary: This annotation suggests ARSB is involved in lysosomal transport.
      The reference describes ARSB being transported TO lysosomes via the
      mannose-6-phosphate receptor pathway, not that ARSB performs transport
      functions.
    action: REMOVE
    reason: This is a misannotation. The reference describes ARSB as a cargo
      being transported to lysosomes, not as performing transport functions.
      ARSB is a lysosomal enzyme that degrades substrates; it does not transport
      materials. This annotation confuses the trafficking of ARSB to lysosomes
      with ARSB having a transport function. This should be removed.
    supported_by:
    - reference_id: PMID:2303452
      supporting_text: Transport of ASB to the lysosomes was accomplished in a
        mannose 6-phosphate receptor-dependent manner
- term:
    id: GO:0030209
    label: dermatan sulfate proteoglycan catabolic process
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1606789
  review:
    summary: ARSB is directly involved in dermatan sulfate degradation by
      removing 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues.
      This is one of the primary catabolic pathways in which ARSB participates,
      as documented in Reactome and the cyberian deep research.
    action: NEW
    reason: This biological process annotation is missing from the existing GOA
      file but is a core function of ARSB. Dermatan sulfate is one of two
      primary substrates for ARSB, and its degradation is blocked in MPS VI
      patients. This annotation is well-supported by Reactome pathway
      documentation and literature.
    supported_by:
    - reference_id: Reactome:R-HSA-1606789
      supporting_text: Arylsulfatase B (ARSB) hydrolyses sulfate from
        N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS;
        Gorham & Cantz 1978)
    - reference_id: file:human/ARSB/ARSB-deep-research-cyberian.md
      supporting_text: 'ARSB acts specifically on two major sulfated glycosaminoglycans:
        Dermatan sulfate (DS): A heteropolysaccharide composed of repeating disaccharide
        units containing iduronic acid and N-acetylgalactosamine-4-sulfate'
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: Hydrolysis of the 4-sulfate groups of the
        N-acetyl-D-galactosamine 4-sulfate units of chondroitin sulfate and
        dermatan sulfate.
- term:
    id: GO:0006027
    label: glycosaminoglycan catabolic process
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-1606789
  review:
    summary: ARSB participates in the broader glycosaminoglycan catabolic
      process through its specific role in degrading dermatan sulfate and
      chondroitin-4-sulfate. This is the parent process that encompasses the
      more specific DS and C4S catabolic activities.
    action: NEW
    reason: This biological process annotation represents the broader catabolic
      category encompassing ARSB function. While more general than the specific
      dermatan sulfate or chondroitin sulfate proteoglycan catabolic processes,
      it appropriately captures ARSB's role in GAG catabolism. The annotation is
      supported by Reactome pathway documentation and literature.
    supported_by:
    - reference_id: Reactome:R-HSA-1606789
      supporting_text: Defects in ARSB are the cause of mucopolysaccharidosis
        type VI (MPSVI) (MIM:253200, also called Maroteaux-Lamy syndrome
    - reference_id: file:human/ARSB/ARSB-deep-research-cyberian.md
      supporting_text: 'ARSB functions within the lysosomal catabolism pathway for
        sulfated glycosaminoglycans. The sequential degradation of dermatan sulfate
        and chondroitin sulfate requires multiple enzymes acting in a specific order.'
    - reference_id: file:human/ARSB/ARSB-uniprot.txt
      supporting_text: 'DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: A form
        of mucopolysaccharidosis, a group of lysosomal storage diseases characterized
        by defective degradation of glycosaminoglycans'
references:
- id: GO_REF:0000003
  title: Gene Ontology annotation based on Enzyme Commission mapping
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to
    orthologs by curator judgment of sequence similarity.
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular
    Location vocabulary mapping, accompanied by conservative changes to GO terms
    applied by UniProt.
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data
    to orthologs using Ensembl Compara.
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning
    models
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods.
  findings: []
- id: PMID:1718978
  title: Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate
    clinical phenotype caused by substitution of valine for glycine at position
    137 of arylsulfatase B.
  findings:
  - statement: The G137V mutation in ARSB severely reduces stability of the
      precursor protein
    supporting_text: The G137V mutation did not affect the synthesis but
      severely reduced the stability of the arylsulfatase B precursor.
  - statement: Most of the mutant precursor is degraded before reaching
      lysosomes
    supporting_text: the majority of the mutant precursor was degraded
      presumably in a compartment proximal to the trans Golgi network and only a
      small amount escaped to the lysosomes
  - statement: This mutation causes an intermediate form of MPS VI
    supporting_text: accounting for the low residual enzyme activity in
      fibroblasts of a patient with the juvenile form of the disease.
- id: PMID:18285341
  title: Distinct effects of N-acetylgalactosamine-4-sulfatase and
    galactose-6-sulfatase expression on chondroitin sulfates.
  findings:
  - statement: ARSB (N-acetylgalactosamine-4-sulfatase) hydrolyzes sulfate
      groups from chondroitin sulfate
    supporting_text: The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase
      (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze
      sulfate groups of CS.
  - statement: Silencing ARSB increases chondroitin-4-sulfate, total chondroitin
      sulfate, and total sulfated GAG content
    supporting_text: Following silencing of ASB or GALNS, total sGAG, C4S, and
      CS increased significantly.
  - statement: Overexpressing ARSB decreases chondroitin-4-sulfate and total
      chondroitin sulfate
    supporting_text: Following overexpression of ASB or GALNS, total sGAG, C4S,
      and CS declined significantly.
  - statement: ARSB expression affects proteoglycan core protein expression
      (syndecan-1, decorin)
    supporting_text: mRNA expression of core proteins of the CS-containing
      proteoglycans, syndecan-1 and decorin, was significantly up-regulated
      following overexpression of ASB
- id: PMID:19306108
  title: Arylsulfatase B regulates colonic epithelial cell migration by effects
    on MMP9 expression and RhoA activation.
  findings:
  - statement: ARSB removes 4-sulfate groups from N-acetylgalactosamine
      4-sulfate in chondroitin-4-sulfate
    supporting_text: Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase;
      4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from
      N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form
      the disaccharide unit of chondroitin-4-sulfate (C4S).
  - statement: ARSB activity is significantly lower in malignant T84 colonic
      cells compared to normal colonocytes
    supporting_text: In the T84 cell line, derived from lung metastasis of
      malignant colonic epithelial cells, the activity of ASB, as well as
      steroid sulfatase, arylsulfatase A, and galactose-6-sulfatase, were
      significantly less than in normal, primary colonic epithelial cells
  - statement: Silencing ARSB increases MMP9 secretion, activated RhoA, and cell
      migration
    supporting_text: When ASB expression was silenced by siRNA in the NCM460
      cells, MMP9 secretion increased to over 3 times the basal level, activated
      RhoA increased * 85%, and cell migration increased * 52%.
  - statement: Overexpressing ARSB decreases MMP9, activated RhoA, and cell
      migration
    supporting_text: Following overexpression of ASB, MMP9 declined 51%,
      activated RhoA declined * 51%, and cell migration decreased * 37%.
  - statement: ARSB regulates invasive phenotype of colonic epithelial cells
      through effects on chondroitin sulfation
    supporting_text: These findings demonstrate marked effects of ASB expression
      on the migratory activity of colonic epithelial cells, activated RhoA, and
      MMP9, and suggest a potential vital role of ASB, due to its impact on
      chondroitin sulfation, on determination of the invasive phenotype of
      colonic epithelial cells.
- id: PMID:2303452
  title: Phylogenetic conservation of arylsulfatases. cDNA cloning and
    expression of human arylsulfatase B.
  findings:
  - statement: Human ARSB is a 533 amino acid protein with a 41 amino acid
      signal peptide
    supporting_text: The deduced amino acid sequence of 533 amino acids contains
      a 41-amino acid N-terminal signal peptide and a mature polypeptide of 492
      amino acid residues.
  - statement: ARSB is synthesized as a 64-kDa precursor and processed to a
      47-kDa mature form
    supporting_text: Pulse-chase labeling showed that ASB was synthesized and
      secreted as a 64-kDa precursor and processed to a 47-kDa mature form in
      BHK cells.
  - statement: ARSB localizes to dense lysosomes via mannose-6-phosphate
      receptor-dependent trafficking
    supporting_text: The 47-kDa ASB form was located in dense lysosomes.
      Transport of ASB to the lysosomes was accomplished in a mannose
      6-phosphate receptor-dependent manner.
  - statement: ARSB is a member of the arylsulfatase gene family showing
      phylogenetic conservation
    supporting_text: Deduced amino acid sequences of human arylsulfatase A,
      human ASB, human steroid sulfatase, human glucosamine-6-sulfatase, and an
      arylsulfatase from sea urchin showed a substantial degree of similarity
      suggesting that they arose from a common ancestral gene and are members of
      an arylsulfatase gene family.
- id: PMID:23533145
  title: In-depth proteomic analyses of exosomes isolated from expressed
    prostatic secretions in urine.
  findings:
  - statement: ARSB was detected in exosomes from prostatic secretions by
      proteomic analysis
    supporting_text: In pooled EPS-urine exosome samples, ~900 proteins were
      detected [including ARSB]
- id: Reactome:R-HSA-1606789
  title: ARSB hydrolyses DS
  findings:
  - statement: ARSB hydrolyzes sulfate from N-acetylgalactosamine 4-sulfate
      units within dermatan sulfate
    supporting_text: Arylsulfatase B (ARSB) hydrolyses sulfate from
      N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS; Gorham
      & Cantz 1978)
  - statement: Conversion of cysteine to 3-oxoalanine (formylglycine) is
      critical for catalytic activity
    supporting_text: The conversion to 3-oxoalanine (formylglycine, FGly) of a
      cysteine residue in eukaryotes, is critical for catalytic activity
  - statement: Defects in ARSB cause mucopolysaccharidosis type VI
      (Maroteaux-Lamy syndrome)
    supporting_text: Defects in ARSB are the cause of mucopolysaccharidosis type
      VI (MPSVI) (MIM:253200, also called Maroteaux-Lamy syndrome (Wicker et al.
      1991)
- id: Reactome:R-HSA-1614362
  title: SUMF1 mediates the oxidation of cysteine to formylglycine, producing
    active arylsulfatases
  findings:
  - statement: SUMF1 performs post-translational modification of ARSB required
      for activity
    supporting_text: SUMF1 mediates the oxidation of cysteine to formylglycine,
      producing active arylsulfatases
  - statement: This modification occurs during ARSB biosynthesis
    supporting_text: SUMF1 mediates the oxidation of cysteine to formylglycine,
      producing active arylsulfatases [during biosynthesis]
- id: Reactome:R-HSA-1793207
  title: ARSB hydrolyses C4S/C6S chains
  findings:
  - statement: ARSB with calcium cofactor hydrolyzes sulfate from
      N-acetylgalactosamine 4-sulfate or 6-sulfate units in chondroitin sulfate
    supporting_text: Arylsulfatase B using calcium cofactor (ARSB:Ca2+)
      hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate)
      units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
  - statement: Formylglycine modification is critical for catalytic activity
    supporting_text: The conversion to 3-oxoalanine (formylglycine, FGly) of a
      cysteine residue in eukaryotes, is critical for catalytic activity, based
      on similarity to the prototypical arylsulfatase ARSA
- id: Reactome:R-HSA-2282889
  title: Defective ARSB does not hydrolyse C4S/C6S chains
  findings:
  - statement: Loss of ARSB function prevents degradation of chondroitin sulfate
      chains
    supporting_text: Defective ARSB does not hydrolyse C4S/C6S chains
  - statement: This leads to MPS VI pathology
    supporting_text: Defective ARSB does not hydrolyse C4S/C6S chains [leading
      to MPS VI]
- id: Reactome:R-HSA-6798751
  title: Exocytosis of azurophil granule lumen proteins
  findings:
  - statement: ARSB is present in azurophil granules of neutrophils
    supporting_text: Exocytosis of azurophil granule lumen proteins
  - statement: These granules can undergo exocytosis, releasing ARSB
      extracellularly
    supporting_text: Exocytosis of azurophil granule lumen proteins
- id: Reactome:R-HSA-6800434
  title: Exocytosis of ficolin-rich granule lumen proteins
  findings:
  - statement: ARSB is present in ficolin-1-rich granules
    supporting_text: Exocytosis of ficolin-rich granule lumen proteins [ARSB is
      present]
  - statement: These specialized neutrophil granules can release ARSB through
      exocytosis
    supporting_text: Exocytosis of ficolin-rich granule lumen proteins
- id: Reactome:R-HSA-9036065
  title: Defective ARSB does not hydrolyse DS
  findings:
  - statement: Loss of ARSB function prevents degradation of dermatan sulfate
    supporting_text: Defective ARSB does not hydrolyse DS
  - statement: This contributes to MPS VI pathology
    supporting_text: Defective ARSB does not hydrolyse DS [contributing to MPS
      VI pathology]
- id: file:human/ARSB/ARSB-uniprot.txt
  title: UniProt entry for ARSB (P15848)
  findings:
  - statement: ARSB removes sulfate groups from chondroitin-4-sulfate and
      regulates its degradation
    supporting_text: Removes sulfate groups from chondroitin-4-sulfate (C4S) and
      regulates its degradation
  - statement: Involved in regulation of cell adhesion, cell migration, and
      invasion in colonic epithelium
    supporting_text: Involved in the regulation of cell adhesion, cell migration
      and invasion in colonic epithelium
  - statement: Regulates neurite outgrowth and neuronal plasticity in CNS
      through control of sulfate GAGs and neurocan
    supporting_text: In the central nervous system, is a regulator of neurite
      outgrowth and neuronal plasticity, acting through the control of sulfate
      glycosaminoglycans and neurocan levels
  - statement: Requires calcium cofactor (binds 1 Ca2+ per subunit)
    supporting_text: 'COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds 1
      Ca(2+) ion per subunit.'
  - statement: Conversion of Cys-91 to 3-oxoalanine (formylglycine) is critical
      for catalytic activity
    supporting_text: The conversion to 3-oxoalanine (also known as
      C-formylglycine, FGly), of a serine or cysteine residue in prokaryotes and
      of a cysteine residue in eukaryotes, is critical for catalytic activity.
  - statement: Deficiency causes mucopolysaccharidosis type VI (MPS VI)
    supporting_text: 'DISEASE: Mucopolysaccharidosis 6 (MPS6) [MIM:253200]: A form
      of mucopolysaccharidosis, a group of lysosomal storage diseases characterized
      by defective degradation of glycosaminoglycans'
- id: file:human/ARSB/ARSB-deep-research-perplexity-lite.md
  title: Deep research on ARSB gene
  findings:
  - statement: ARSB is predominantly a lysosomal enzyme with extra-lysosomal
      localization at cell membranes in some cell types
    supporting_text: 'Primary: ARSB is predominantly a lysosomal enzyme. Extra-lysosomal:
      Immunohistochemistry and immunofluorescence studies have also detected ARSB
      at the cell membrane'
  - statement: ARSB regulates extracellular matrix remodeling, cell migration,
      and signaling pathways
    supporting_text: 'Extracellular matrix remodeling: ARSB influences the composition
      and turnover of the extracellular matrix, affecting cell adhesion, migration,
      and invasion'
  - statement: ARSB has tumor suppressor activity; reduced expression linked to
      cancer progression
    supporting_text: 'Cancer: Reduced ARSB expression is linked to altered proteoglycan
      expression and tumor progression in prostate and colonic epithelial cells. Acts
      as a tumor suppressor'
  - statement: ARSB regulates neuronal development through control of sulfated
      GAGs and neurocan
    supporting_text: 'Neuronal development: In the central nervous system, ARSB regulates
      neurite outgrowth and neuronal plasticity by controlling sulfate GAG and neurocan
      levels'
  - statement: Enzyme replacement therapy with recombinant ARSB is standard
      treatment for MPS VI
    supporting_text: Enzyme replacement therapy (ERT) with recombinant ARSB is
      the standard treatment for MPS VI, aiming to reduce GAG accumulation and
      ameliorate symptoms
- id: file:human/ARSB/ARSB-deep-research-cyberian.md
  title: Deep research on ARSB gene (cyberian)
  findings:
  - statement: ARSB catalyzes removal of 4-sulfate groups from
      N-acetylgalactosamine-4-sulfate residues at the non-reducing end of GAG
      chains
    supporting_text: 'Arylsulfatase B (ARSB) is a sulfohydrolase that catalyzes the
      removal of 4-sulfate groups from N-acetylgalactosamine-4-sulfate residues located
      at the non-reducing end of glycosaminoglycan (GAG) chains. The systematic name
      of the enzyme is N-acetyl-D-galactosamine-4-sulfate 4-sulfohydrolase (Bond et
      al., 1997; Valayannopoulos et al., 2010).'
  - statement: ARSB also demonstrates activity against
      N-acetylglucosamine-4-sulfate as a substrate
    supporting_text: 'Notably, ARSB also demonstrates activity against N-acetylglucosamine-4-sulfate
      as a substrate (Bond et al., 1997). This activity is consistent with the enzyme''s
      ability to act on related 4-sulfated hexosamine residues, though its primary
      physiological substrates remain the GAG chains of DS and C4S.'
  - statement: Formylglycine (FGly91) is found in a sulfate-modified form at the
      active site, and calcium ion is essential for catalysis
    supporting_text: 'The crystal structure of human ARSB (PDB: 1FSU), solved at 2.5
      A resolution, revealed that: Formylglycine (FGly91) is found in a sulfate-modified
      form (oxo-alanine sulfate ester) in the active site; A divalent calcium ion
      (Ca2+) is coordinated at the active site and is essential for catalysis; The
      calcium ion binds directly to the sulfate group of the modified cysteine residue
      (Bond et al., 1997)'
  - statement: Sulfate hydrolysis proceeds through
      transesterification-elimination (TE) mechanism
    supporting_text: 'The sulfate hydrolysis mechanism proceeds through either an
      addition-hydrolysis (AH) or transesterification-elimination (TE) pathway, with
      current evidence favoring the TE mechanism. In this mechanism: The aldehyde
      of formylglycine becomes hydrated to a gem-diol; One hydroxyl of the gem-diol
      attacks the substrate sulfur, forming a covalent enzyme-sulfate intermediate;
      Elimination releases the product and regenerates the aldehyde (Hanson et al.,
      2004)'
  - statement: ARSB is targeted to lysosomes via the mannose-6-phosphate (M6P)
      receptor pathway
    supporting_text: 'The mature enzyme of 533 amino acids is generated after cleavage
      of the signal peptide and is targeted to lysosomes via the mannose-6-phosphate
      (M6P) receptor pathway (Braulke & Bonifacino, 2009).'
  - statement: ARSB participates in extracellular GAG remodeling at the plasma
      membrane and in the extracellular matrix
    supporting_text: 'While primarily a lysosomal enzyme, ARSB also exhibits extra-lysosomal
      localization. Studies have demonstrated ARSB presence at the plasma membrane
      and in the extracellular matrix, where it participates in local GAG remodeling
      (Bhattacharyya et al., 2009).'
  - statement: ARSB modulates galectin-3 binding and SHP-2 phosphatase activity
      through control of chondroitin sulfation
    supporting_text: 'Beyond its housekeeping role in GAG catabolism, ARSB has emerged
      as a regulator of cellular signaling and gene expression. By controlling the
      sulfation status of cell-surface and extracellular GAGs, ARSB modulates: Galectin-3
      binding: The degree of chondroitin 4-sulfation affects galectin-3 sequestration
      and release, influencing downstream signaling; SHP-2 phosphatase activity: ARSB
      activity impacts SHP-2 localization and function (Bhattacharyya et al., 2022)'
  - statement: ARSB functions as a tumor suppressor, transcriptional mediator,
      and regulator of cellular signaling
    supporting_text: 'These broader roles suggest ARSB functions as a tumor suppressor,
      transcriptional mediator, and regulator of cellular signaling beyond its classical
      lysosomal function.'
  - statement: The ARSB protein structure contains an active site domain
      resembling alkaline phosphatase
    supporting_text: 'Despite lacking detectable sequence similarity, the ARSB active
      site domain closely resembles that of alkaline phosphatase. The calcium in ARSB
      superimposes on one of the zinc ions in alkaline phosphatase, and the oxo-alanine
      sulfate ester superimposes on the phosphate ion in alkaline phosphatase (Bond
      et al., 1997)'
  - statement: Over 220 unique ARSB variants have been identified causing MPS VI
    supporting_text: 'Genetic heterogeneity: Over 220 unique ARSB variants have been
      identified, including Missense variants: 59.5%, Small deletions: 13.5%, Nonsense
      mutations: 12.0%, Splice site variants: 5.0%'
core_functions:
- description: Hydrolyzing 4-sulfate groups from N-acetylgalactosamine residues
    within dermatan sulfate and chondroitin-4-sulfate glycosaminoglycan chains
    in the lysosomal lumen
  molecular_function:
    id: GO:0003943
    label: N-acetylgalactosamine-4-sulfatase activity
  directly_involved_in:
  - id: GO:0030209
    label: dermatan sulfate proteoglycan catabolic process
  - id: GO:0030207
    label: chondroitin sulfate proteoglycan catabolic process
  - id: GO:0006027
    label: glycosaminoglycan catabolic process
  locations:
  - id: GO:0043202
    label: lysosomal lumen
  substrates:
  - id: CHEBI:18376
    label: dermatan sulfate
  - id: CHEBI:18250
    label: chondroitin 4'-sulfate
  supported_by:
  - reference_id: PMID:19306108
    supporting_text: Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase;
      4-sulfatase; ARSB) is the enzyme that removes 4-sulfate groups from
      N-acetylgalactosamine 4-sulfate, which combines with glucuronate to form
      the disaccharide unit of chondroitin-4-sulfate (C4S).
  - reference_id: PMID:18285341
    supporting_text: The sulfatase enzymes, N-acetylgalactosamine-4-sulfatase
      (arylsulfatase B (ASB)) and galactose-6-sulfatase (GALNS) hydrolyze
      sulfate groups of CS.
  - reference_id: Reactome:R-HSA-1606789
    supporting_text: Arylsulfatase B (ARSB) hydrolyses sulfate from
      N-acetylgalactosamine 4-sulfate units within dermatan sulfate (DS)
  - reference_id: Reactome:R-HSA-1793207
    supporting_text: Arylsulfatase B using calcium cofactor (ARSB:Ca2+)
      hydrolyses sulfate from N-acetylgalactosamine 4-sulfate (or 6-sulfate)
      units (GalNAc 4-sulfate or GalNAc 6-sulfate) within chondroitin sulfate
  - reference_id: PMID:2303452
    supporting_text: The 47-kDa ASB form was located in dense lysosomes.
      Transport of ASB to the lysosomes was accomplished in a mannose
      6-phosphate receptor-dependent manner.
  - reference_id: file:human/ARSB/ARSB-uniprot.txt
    supporting_text: 'COFACTOR: Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Note=Binds 1
      Ca(2+) ion per subunit.'
  - reference_id: file:human/ARSB/ARSB-deep-research-cyberian.md
    supporting_text: 'The crystal structure of human ARSB (PDB: 1FSU), solved at 2.5
      A resolution, revealed that: Formylglycine (FGly91) is found in a sulfate-modified
      form (oxo-alanine sulfate ester) in the active site; A divalent calcium ion
      (Ca2+) is coordinated at the active site and is essential for catalysis'
  - reference_id: file:human/ARSB/ARSB-deep-research-cyberian.md
    supporting_text: 'The sulfate hydrolysis mechanism proceeds through either an
      addition-hydrolysis (AH) or transesterification-elimination (TE) pathway, with
      current evidence favoring the TE mechanism.'

ARSB

Gene Description

Existing Annotations Review

Core Functions

Hydrolyzing 4-sulfate groups from N-acetylgalactosamine residues within dermatan sulfate and chondroitin-4-sulfate glycosaminoglycan chains in the lysosomal lumen

References

Deep Research

Cyberian

Comprehensive Research Report: ARSB (Arylsulfatase B)

Gene/Protein Identity Verification

1. Enzymatic Function and Catalytic Mechanism

1.1 Reaction Catalyzed

1.2 Substrate Specificity

1.3 Catalytic Mechanism and Active Site

2. Subcellular Localization

2.1 Lysosomal Targeting

2.2 Extracellular Localization

3. Biological Processes and Pathways

3.1 Glycosaminoglycan Degradation Pathway

3.2 Tissue-Specific GAG Accumulation

3.3 Broader Regulatory Functions

4. Structural Biology

4.1 Gene and Protein Structure

4.2 Crystal Structure

4.3 Post-Translational Modifications

5. Disease Associations

5.1 Mucopolysaccharidosis Type VI (MPS VI; Maroteaux-Lamy Syndrome)

5.2 Therapeutic Approaches

6. Conclusions

References

Online Resources Consulted

Citations

Falcon

Citations

Perplexity

Citations

📄 View Raw YAML